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Abstract
The peripheral immune system plays a role in delayed neural injury after stroke. This
response originates from the spleen as splenectomy prior to middle cerebral artery
occlusion (MCAO) in rats significantly reduces infarct volume in the brain. This research
is based on the hypothesis that inhibiting the splenic response will reduce
neurodegeneration after stroke. Studies in animals have implicated lymphocytes as the
immune cell type that is detrimental following MCAO. Interferon gamma (IFNγ) has been
identified as a pro-inflammatory cytokine that is also detrimental following stroke. IFNγ is
important because it activates microglia and macrophages in a pro-inflammatory nature
that increases neural injury following stroke. Therefore IFNγ was examined in the brain
and the spleen following MCAO. IFNγ protein was elevated at 24 h in the spleen and at
72 h in the brain post MCAO. Microglia/macrophages become maximally activated at 72
h in the brain after MCAO. Splenectomy decreases the levels of IFNγ in the brain
following MCAO. Systemic administration of IFNγ reversed the protective effects of
splenectomy.

The cellular response to MCAO was examined next because of the difference in time
between the spike in IFNγ in the spleen and the delayed increase in the brain. The
cellular response from the spleen was studied by labeling splenocytes five days prior to
MCAO with a fluorescein dye. Tissues were examined 48 and 96 h post MCAO or sham
MCAO for fluorescence. These cells were released from the spleen into circulation at 48

viii

h post MCAO and migrated to the brain where the cells produced IFNγ at 96 h post
MCAO.

IFNγ appears to play a role in the splenic response to stroke. One protein that is up
regulated by cells that have been activated by IFNγ, interferon-inducible protein 10 (IP10) is part of the inflammatory cycle driven by IFNγ. IP-10 recruits more IFNγ producing
T helper (Th) cells to the site of injury. IP-10 has the unique ability to attract Th1 cells, the
pro-inflammatory Th cells, and inhibit Th2 cells, the anti-inflammatory Th cells. This leads
to more IFNγ production as IFNγ is the signature cytokine of a Th1 response. IP-10 is
significantly increased in the brain at 72 h post MCAO, similar to IFNγ expression. In the
spleen IP-10 increased at 24 h and remained elevated out to 96 h following MCAO. IFNγ
signaling was inhibited by utilizing an IFNγ neutralizing antibody administered beginning
24 h post MCAO. The IFNγ antibody treated group had decreased infarct volumes, IP-10
levels in the brain, and appeared to have decreased T cells in the ipsilateral hemisphere
at 96 h post MCAO.

Following ischemic stroke splenocytes are released into circulation and migrate to the
brain. They release IFNγ to activate microglia/macrophages in a proinflammatory
phenotype causing an increase in IP-10 levels. IP-10 then potentiates the Th1 driven
inflammation which inhibits the Th2 response. The elevated levels of IFNγ increase
neural injury following MCAO. Blocking IFNγ selectively blocks the inflammatory facet of
the immune response to reduce stroke induced neurodegeneration. This leaves the
other immune responses intact and able to contribute to tissue repair, regeneration, and
able to respond to infections. Selectively inhibiting IFNγ signaling is a promising stroke
therapeutic.
ix

Background and Significance
Stroke:
Stroke Pathology
Strokes are caused by a disruption of blood flow to the brain, which results in brain
damage to the areas supplied by the effected blood vessel. Loss of blood flow can result
in two different types of stroke: ischemic stroke, caused by a clot, or hemorrhagic stroke,
intracerebral hemorrhage (ICH), caused by the rupture of a blood vessel. Ischemic
strokes account for 87 percent of all strokes and can be caused by two different
mechanisms embolism or thrombosis. Cerebral embolisms occur when a blood clot
forms at the point of occlusion in the vessel, whereas cerebral thrombosis occurs when a
clot from another area of the body travels to the brain and becomes lodged in the
occluded blood vessel. Occlusion of the larger vessels in the brain can have catastrophic
effects because large areas of the brain are affected.

Stroke is the fourth leading cause of death in the United States, 129,000 deaths in 2011,
and leading cause of disability. Approximately 795,000 strokes occur each year, of which
185,000 are recurrent strokes. There is a 40% increase in risk of stroke in the first five
years following an initial stroke. Usually recurrent strokes are more disabling and have
higher mortality. In 2010 there were seven million stroke survivors over age 20 in the
United States. While stroke is down to the fourth leading cause of death from the third
leading cause, it still remains the leading cause of disability. The reason stroke is the
1

leading cause of disability is because 50% of patients experienced some hemiparesis,
30% were unable to walk without assistance, 26% were dependant on assistance with
activities of daily living, 19% had aphasia, 35% had depressive symptoms, and 26%
were in nursing homes. This leads to a high financial burden on society as stroke
resulted in $73.7 billion in total direct and indirect costs in United States in 2010 (Roger
et al. 2012).

Risk Factors
There are several risk factors for stroke that can include medical conditions, life style
choices, genetic factors, and a person’s family history. Common risk factors for stroke
include high blood pressure, high cholesterol, diabetes, atherosclerosis, atrial fibrillation,
smoking, alcohol consumption, physical inactivity, sleep apnea, and obesity. The risk for
stroke is also higher in individuals over the age of 55. Men have a higher risk of stroke
compared to women. Non-Caucasian individuals have a higher rate of stroke than
Caucasians. Individuals with a family history of stroke are at a higher risk and people
who have had a previous stroke or transient ischemic attack (TIA) are at risk of having
another stroke. TIA greatly increases a person’s risk of stroke as 40% of people with TIA
have a stroke, 5% within 2 days and 10-15% within 3 months of the initial TIA (Roger et
al. 2012).

Treatment
Recombinant tissue plasminogen activator (rTPA) is the only FDA approved treatment
for ischemic stroke, with a treatment window of 4.5 h, which allows only 3-5% of patients
to be eligible to receive treatment. Additionally, rTPA can cause transformation of an
ischemic stroke into a hemorrhagic stroke. Currently there are no pharmaceutical
treatments for hemorrhagic stroke, only strategies to manage the symptoms. There are
2

extensive exclusion criteria for the use of rTPA in order to minimize the risk for bleeding
or hemorrhagic transformation. Recombinant TPA is contraindicated in individuals with
ICH, intracranial or intraspinal surgery within the last three months, history of pervious
stroke or ICH, uncontrolled blood pressure (>185 mm Hg systolic or >110 mm Hg
diastolic), individuals over the age of 75, seizure at the onset of stroke, active internal
bleeding, arteriovenous malformation, aneurysm, intracranial neoplasm, the use of oral
anticoagulants, heparin administration within the previous 48 h, or a platelet count
<100,000/mm3. Individuals with National Institutes of Health Stroke Scale (NIHSS)
scores greater than 22 at presentation are excluded (Genentech 2011), as individuals
with NIHSS scores >20 are at a higher risk of ICH (Adams et al. 2003). Diabetic
individuals and individuals with hyperglycemia have an increased risk of ICH with
thrombolytic therapy (Martini and Kent 2007).

The therapeutic window for rTPA treatment in ischemic stroke is narrow at 4.5 h making
it very difficult for stroke patients as many do not recognize the need for treatment within
that time frame. Stroke patients must first identify that they are having a stroke and then
they must seek medical treatment. After getting medical attention, the possibility of a
cerebral hemorrhage must be ruled out as rTPA can only be used for embolic strokes.
Once all these steps are performed the individual may still be ineligible to receive rTPA
due to the strict inclusion criteria for the use of rTPA.

Animal Models of Stroke
There are different types of experimental models of both ischemic strokes and ICH. One
model of ICH involves injecting bacterial collagenase type IV directly into the striatum of
animals. The collagenase disrupts the integrity of the basal lamina which leads to leaky
blood vessels and a brain bleed (MacLellan et al. 2010). Ischemic strokes can be further
3

divided into two types of ischemia that can cause neural injury: global ischemia and focal
ischemia. Global ischemia occurs when there is loss of blood flow to the whole brain
such as during a myocardial infarction (MI) when blood flow to the whole body is
stopped. Focal ischemia only affects certain areas of the brain and can be caused by a
blood clot occluding a blood vessel. In animal models, global ischemia can be produced
by temporarily stopping the heart which stops blood flow to the entire body including the
brain. Focal cerebral ischemia can be performed to create an embolic stroke. While
models of embolic stroke can be caused permanently by cauterizing a cerebral artery,
most involve the middle cerebral artery (MCA), as the MCA is the most commonly
occluded vessel in people. This method involves performing a craniotomy to visualize
the cerebral vasculature and creates a small focal cortical lesion. Another method of
creating a permanent occlusion is by injecting a clot into the common carotid artery,
which becomes lodged in the smaller vasculature. One advantage to this procedure is
that the animal is awake at the time of occlusion and it is a useful model to study
thrombolytic therapies. However, this model is not highly reproducible as the clot can
become lodged in numerous different arteries. A minimally invasive procedure to induce
focal cerebral ischemia involves photochemical thrombus formation by systemically
administering the dye Bengal Rose. A blood clot forms when a laser is positioned
against the skull and illuminated. The resulting focal infarct is a small cortical lesion
without a penumbra or area of salvable tissue. One of the most commonly used
experimental stroke models is the intraluminal filament model, also referred to as the
middle cerebral artery occlusion (MCAO). This model involves inserting an embolus, a
monofilament, into the external carotid artery and advancing the embolus to the origin of
the MCA occluding blood flow to MCA territory. The monofilament can be tied off
creating a permanent occlusion (pMCAO) or removed after a period of time to create an
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ischemic reperfusion injury, also referred to as a transient occlusion (tMCAO) (for a
comprehensive review, see (Braeuninger and Kleinschnitz 2009)).

The Spleen and Ischemic Injuries Including Stroke:
The Immune System
The immune system is made up of a network of organs and cells which come together to
form the functional unit. The two primary organs of the immune system are the bone
marrow and the thymus. The bone marrow is the germinal center for all blood cells and
the site of B cell maturation. T cells leave the bone marrow and mature in the thymus.
Secondary peripheral immune organs include the spleen and lymph nodes. These two
organs are areas where immune cells pool together and these sites are areas of filtration
and immune surveillance. This filtering allows the immune system to quickly mount an
immune response to a pathogen that is found in systemic circulation.

The immune system can be divided into two categories: the innate immune system and
the adaptive immune system. Each system has its own set of specialized cells and
performs specific functions in the clearance of pathogens, tissue recovery from injury,
and surveillance for tumor cells. The innate immune system is made up of neutrophils,
monocytes, and natural killer cells (NK cells). These cells are the first responders to an
immune challenge. Neutrophils are phagocytic cells that primarily engulf and kill evading
or dying cells. Monocytes are known as antigen presenting cells (APCs). Cells of the
monocytic

lineage

include

macrophages,

dendritic

cells,

and

tissue

specific

macrophages including microglia (brain) and Kupffer cells (liver). These cells
phagocytize pathogens and present what they find to T cells via the major
histocompatibility complex (MHC) II. MHC II is found only on APCs and presents T cells
with antigens, where MHC I is expressed on all cells and displays self peptides which
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allow T cells and NK cells to determine if a cell should be present in the body.
Intracellular pathogens will have their peptides expressed in MHC I which will trigger a
cytotoxic response from NK cells or T cells. NK cells are cells of lymphocytic origin but
they are able to recognize infected cells or tumor cells and generate a cytotoxic
response without becoming activated by another cell. NK cells are able to induce
apoptosis in virally or bacterially infected cells or malignant cells without any signals
besides the activation of their receptors. Unlike the adaptive immune system, which can
take days to weeks to generate a response to a pathogen, the innate immune system
can generate an immediate response.

The adaptive immune system consists of lymphocytes, T cells and B cells. The adaptive
immune response takes days to weeks to initiate due to the highly specific nature of the
receptors on T cells and B cells. These B and T cell receptors are very specific for their
epitope on a particular antigen. These cells must come across their specific antigen to
become activated and generate a response. B cells can generate a response without the
signaling of other cells, although T cells can play a role in influencing antibody
production. Activated B cells go on to produce antibodies directed against their specific
antigen. T cells need to be presented with their antigen by APCs. The response
generated by a T cell depends on the type of T cell. Cytotoxic T cells, or CD8+ T cells,
recognize MHC I on cells and will initiate apoptosis in cells which are not presenting self
peptides. Cells which are expressing pathogen peptides in MHC I will trigger a CD8+ T
cell response if the pathogen peptide is the specific antigen for that T cell. The other
subset of T cells is the T helper cells (Th cells), CD4+ T cells; of which there are many
branching Th cell subsets. The two major Th responses are the Th1 response and the
Th2 response. These two responses oppose each other. A Th1 response is considered
pro-inflammatory and is directed against intracellular pathogens, including bacteria and
6

viruses, while the Th2 response is considered anti-inflammatory, is directed at helminths
and is responsible for generating allergic reactions. The main function of Th cells is to
control or influence the immune response by secreting effector molecules or cytokines.
Th cells can orchestrate an immune response by activating different cells of the innate
immune system, cause isotype switching in B cells or recruit specific immune cell
subsets to the area of inflammation. A special subset of Th cells is T regulatory (Treg
cells) cells, which are responsible for stopping an immune response. These cells are
important in ensuring the immune response does not cause additional injury to the
surrounding tissue and in helping to decrease inflammation.

Splenic Physiology
The spleen is a highly vascularized secondary peripheral lymphoid organ. The spleen
has many functions including clearing dying red blood cells, removing hemoglobin from
circulation, removal of bacterial pathogens from circulation, controlling iron homeostasis,
and regulating the immune response and B cell antibody production. The spleen is
divided into the red pulp and the white pulp. The white pulp is made up T cell zones, or
periarteriolar lymphoid sheaths, and B cell follicles. The red pulp contains B cells, NK
cells, and monocytes/macrophages that are in close proximity to the vasculature. This
allows monocytes/macrophages to filter the blood for dying red blood cells, hemoglobin,
and antibody covered bacterial pathogens. Plasma cells or antibody producing B cells
are the specific type of B cells found in the red pulp. This location in the spleen allows for
rapid delivery of antibodies into circulation (Mebius and Kraal 2005). NK cells in the red
pulp resemble NK cells found in circulation (Witte et al. 1990). The white pulp is split into
two areas, one for T cells and another for B cells. The T cell zones allow naïve T cells to
be in close proximity to the arteriole blood supply. In addition to T cells, dendritic cells
are present in the T cell zones to present naïve T cells with antigens the dendritic cells
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find in the blood. Once activated, T cells leave the spleen and initiate an immune
response. Specialized macrophages are found in the marginal zones of the white pulp
which recognize both bacterial and viral blood borne pathogens. These cells are
important in secreting cytokines and chemokines that influence T and B cells. Polyclonal
expansion of B cells and isotype switching occur in the B cell follicles. Due to the close
proximity of the cells within the white pulp, T cells can influence B cell isotype switching
(Mebius and Kraal 2005).

The splenic capsule is made up of smooth muscles that express α1 adrenergic
receptors. Activation of the α1 receptors leads to contraction of the smooth muscles and
a decrease in spleen size. In addition to being an immune cell reservoir, the spleen is
also reservoir for red blood cells. During times of physical stress, the spleen has been
shown to contract and release red and white blood cells into systemic circulation
(Bakovic et al. 2005; Bakovic et al. 2003). The spleen is the largest reservoir of
undifferentiated non-tissue specific monocytes and, in humans, contains half of the
monocytic cell population. These cells have been shown to be released following MI and
have detrimental effects on the damaged tissue as well as prevent tissue healing
(Swirski et al. 2009).

The Role of the Spleen in Ischemic Injuries
The spleen is large reservoir of immune cells that can generate pro-inflammatory
responses to various ischemic injuries. Splenectomy is protective in other ischemic
injuries including the liver, intestines, kidneys, and heart. Removal of the spleen
immediately prior to ischemic/reperfusion (IR) injury of the liver results in decreased
levels of alanine aminotransferase levels (ALT) a biochemical markers of liver injury, and
decreased hepatocellular injury. Additionally splenectomy reduced the number of
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polymorphonuclear cells in the liver following liver IR (Okuaki et al. 1996). A later study
found that splenectomy prior to hepatic IR reduced the elevated levels of two liver
enzymes associated with liver damage, ALT and aspartate aminotransferase (AST), as
well as tumor necrosis factor alpha (TNFα), and myeloperoxidase (MPO) activity in the
liver, which is a marker of the presence of neutrophils.

In addition, hepatic IR is

associated with injury to other organs including the kidneys, lungs, and intestines and
splenectomy reduced cell apoptosis and caspase 3 signaling in all four organs (Jiang et
al. 2007). Intestinal IR has been linked to acute lung injury. Kupffer cells in the liver
become activated in intestinal IR. Blocking Kupffer cell activation using gadolinium
chloride or splenectomy prior to intestinal IR resulted in significantly decreased levels of
TNFα, interleukin 6 (IL-6), MPO, and malondialdehyde assay (MDA), a marker of lipid
peroxidation, in the lungs. Polymorphonuclear leukocyte (PMNL) counts were also
significantly decreased in the lungs in the gadolinium chloride and splenectomy groups.
Gadolinium chloride treatment and splenectomy did not reduce the levels of any of the
outcome measures down to sham IR operated groups (Savas et al. 2003). Kupffer cells
also play a detrimental role following renal IR. Gadolinium chloride was administered or
splenectomy was performed prior to renal IR. Both the gadolinium chloride and
splenectomy groups had decreased histopathological changes compared to the renal IR
group. In addition, serum ALT, AST, BUN, and creatinine levels were significantly
increased in the renal IR group but significantly decreased in the gadolinium chloride
and splenectomy groups. Tissue levels of MDA, MPO, and lactate dehydrogenase
(LDH), a marker of cell death, were significantly elevated in the renal IR groups and
significantly decreased in the treatment groups. Renal IR also decreased glutathione
(GSH) levels and Na+/K+ ATPase activity while treatment with gadolinium chloride or
splenectomy restored the activity of these two proteins (Kara et al. 2009). The studies on
intestinal IR and renal IR both concluded that splenectomy was protective because of
9

the removal of a large reservoir of monocytes. Monocytes have also been found to play
an important role in exacerbating injury following myocardial infarction (MI).
Sequestering splenic monocytes in the spleen with enalapril, an angiotensin-converting
enzyme (ACE) inhibitor, or splenectomy prior to experimental MI decreased
inflammation and infarct size (Leuschner et al. 2010).

Monocytes have been shown to play a detrimental role in ischemic pathology in many
organs. As the spleen contains a majority of the monocytes in the body, this suggests
these cells are responsible for IR organ damage. This has lead to the conclusion that the
spleen is an important mediator of post IR injury tissue damage. Additionally blocking
Kupffer cell activation with gadolinium chloride was as efficacious as splenectomy in
renal and intestinal IR. These studies indicated that the spleen activates Kupffer cells in
a pro-inflammatory state that increases tissue damage following IR injuries. Kupffer
cells, like microglia, are tissue-specific macrophages. If the spleen causes Kupffer cell
activation following IR injuries to the kidney and intestines, then the spleen might be
negatively influencing microglia in the same manner, which would increase neural injury
following ischemic brain injury.

Removal of the spleen is also protective in pMCAO, tMCAO, ICH, and traumatic brain
injury (TBI) (Ajmo et al. 2008; Jin et al. 2013; Lee et al. 2008; Das et al. 2011; Li et al.
2011; Walker et al. 2010). Splenectomy prior to pMCAO in rats decreases infarct volume
and the number of neutrophils and activated microglia in the brain (Ajmo et al. 2008). In
mice, splenectomy prior to tMCAO decreased infarct volume, brain IFNγ levels, and did
not increase post stroke infections (Jin et al. 2013). Brain water content was significantly
lower in splenectomized animals compared to intact animals prior to ICH (Lee et al.
2008). Splenectomy immediately after TBI was found to decrease neural injury in two
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different models of experimental TBI (Walker et al. 2010; Das et al. 2011; Li et al. 2011),
which creates areas of ischemia from vessel damage and edema following TBI. As an
alternative to splenectomy, irradiation of the spleen 4 h post tMCAO decreases infarct
volume in rats similar to the effects of splenectomy prior to pMCAO. Splenic irradiation
causes a temporary decrease in splenocytes which does not result in wide spread
immunosuppression (Ostrowski et al. 2012). These experiments all demonstrate that the
spleen plays an inflammatory role in brain injuries and ischemic injuries to other organs.
Further investigation is needed to determine the mechanisms by which the spleen is
inflammatory following ischemic injuries.

Spleen Size Decreases following Permanent and Transient MCAO
The spleen has been found to decrease in size following pMCAO in rats (Vendrame et
al. 2006) and tMCAO in mice (Offner et al. 2006b). The spleen transiently decreases in
size from 24 to 72 h following pMCAO in rats (Seifert et al. 2012). The transient changes
seen in pMCAO are likely due to the catecholamine (CA) surge which occurs following
damage to the insular cortex, an area mainly perfused by the MCA. Activation of the α1
adrenergic receptors on the splenic smooth muscle capsule results in contraction of the
splenic capsule, which leads to the decrease in spleen size. Administration of prazosin,
an α1 adrenergic receptor blocker, prevents the decrease in spleen size following
pMCAO (Ajmo et al. 2009). Spleen size has also been inversely correlated with infarct
volume in rats following pMCAO, with smaller spleen sizes correlating with larger infarcts
(Vendrame et al. 2006). The splenic response in mice following tMCAO appears to be
different from the response observed in rats following pMCAO. The spleens of mice
continually decrease in size following tMCAO out to 96 h. This decrease in spleen size
appears to be due to apoptosis of the spleen and a loss of the germinal B cell centers.
The only immune cell population that has been shown to decrease in number following
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tMCAO in mice are B cells (Offner et al. 2006b). There are several reasons that could
explain the observed differences in the splenic response to MCAO. The studies were
performed in different animal species, mice compared to rats, and the observations were
made in two different injury models, transient versus permanent MCAO. There are many
factors that could result in the differences seen in mice and rats following MCAO. The
only way to determine how the spleen responds to stroke is to study stroke patients.

Studies are currently being conducted which examine spleen size in stroke patients to
truly understand the role the spleen plays in patients following stroke. One such study is
currently being conducted and preliminary data indicates that the spleen in individuals
who have suffered a stroke decreases in volume initially, < 6 h to 3 days, and slowly
begins to increase in volume starting at day 4 and continuing out to 8 days following the
stroke. An individual who suffered a severe stroke and ultimately died had spleen
volumes that continued to decrease as their NIHSS score also progressively increased,
indicating a worsening of neurological symptoms. Two other individuals who had better
outcomes had spleens that initially decreased in volume and began to increase in
volume as their NIHSS scores decreased. One of the two individuals had their spleen
volume measured 90 days following their stroke and at 90 days the individual’s spleen
volume was not different from the measurement taken at discharge (Sahota et al. 2013).

Stem Cell Therapies and the Spleen
Human umbilical cord blood (HUCB) cells (Vendrame et al. 2004; Makinen et al. 2006;
Zhang et al. 2011), hematopoietic stem cells (HSC) (Schwarting et al. 2008), bone
marrow stem cells (BMSC) (Keimpema et al. 2009), and neural stem cells (NSC) (Lee et
al. 2008) have all been shown to reduce neural injury in experimental models of stroke.
Stem cells are more efficacious when administered systemically compared to
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intracerebral administration. When administered systemically, stem cells migrate to the
spleen (Lee et al. 2008; Schwarting et al. 2008; Keimpema et al. 2009; Vendrame et al.
2004), which may be why the cells are more efficacious via this injection route. Even
NSCs migrate to the spleen following intracerebral hemorrhage and are not as
efficacious when combined with splenectomy. NSCs were found to be in direct contact
with CD11b+ splenocytes (Lee et al. 2008). This suggests that part of the
neuroprotection provided by NSCs involves interacting with the spleen. HUCB cells are
another cell type that has been shown to interact with splenocytes. Systemic
administration of HUCB cells 24 h post pMCAO results in altered splenic T cell
responses to concovalin A. Splenic T cells had decreased cell proliferation and
decreased production of inflammatory cytokines TNFα and interferon gamma (IFNγ) with
an increase in the production of the anti inflammatory cytokine interleukin 10 (IL-10).
HUCB cells also prevent the decrease in spleen size seen at 48 h in rats. This effect is
thought be mediated by HUCB cells sequestering immune cells in the spleen following
MCAO, preventing their release into systemic circulation (Vendrame et al. 2006). This
set of experiments suggests stem cell therapies work in part by modulating the immune
response to stroke, specifically at the level of the spleen.

The Initial Cascade of Neural Death following Stroke
The hypoxic and glucose deprived environment that develops following ischemic stroke
leads to cellular dysfunction and cell death through necrosis or apoptosis. In an attempt
to keep up with the high energy demands in the brain, neural cells switch to anaerobic
cellular respiration. Cell membranes become damaged from the resulting build up of
reactive oxygen and nitrogen free radicals, which leads to cellular edema and necrosis.
Additionally, as neurons and astrocytes die there is a release of glutamate that
compromises more neurons through glutamate excitotoxicity. The activation of glutamate
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receptors leads to excessive intracellular calcium release, edema, and caspase
activation resulting in apoptosis (Lipton 1999). All of these mechanisms lead to early cell
death in the core of the infarct, the area directly perfused by the occluded artery.

In addition to neural cell death, activation of matrix metalloproteinases (MMPs) lead to
the opening of the blood-brain-barrier (BBB). Shortly after occlusion the BBB is broken
down transiently by MMP-2. Later, at 48 h post MCAO, up regulation of MMP-9 leads to
a prolonged disruption of the BBB (Candelario-Jalil et al. 2009). This break down in the
BBB allows neural antigens into the peripheral circulation. The leaky BBB contributes to
enhanced neural injury by increasing edema as intracranial pressure builds from the
influx of excess fluid. This BBB dysfunction also allows the immune system to come in
contact with these neural antigens and generate an immune response to the brain.

The Peripheral Immune Response to Stroke:
Cellular Response
The CNS has a structurally different network of capillaries that are different from the rest
of the body. Within the CNS, the endothelial cells closely control which substances or
cells can enter the brain or spinal cord. The specialized endothelial cells have
extracellular tight junctions connecting neighboring cells together and these cells are
closely associated with a basement membrane and extracellular matrix. The absence of
fenestrations in the endothelial cells and reduced pinocytotic activity also contribute to
the protection of the brain by the cerebral vasculature. This restricted access to the brain
created by these cells is known as the BBB (de Vries et al. 1997). The BBB protects the
brain from exposure to anything harmful in the blood. This includes protection from the
peripheral immune system under normal healthy conditions. Generally, the only immune
cells present in the brain are the endogenous macrophages, microglia. Occasionally a T
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cell may enter the brain but due to the decreased expression of MHC molecules in the
CNS, the T cell leaves the brain within 24-48 h (Miller 1999). This makes the brain an
immunoprivileged site which is beneficial in protecting the brain from systemic
inflammation. However, neural antigens can be seen as foreign to the immune system
resulting in immune responses generated against neural antigens which are present in
systemic circulation following brain injuries, including stroke.

The peripheral immune system, both the innate and the adaptive systems, plays an
important role in the inflammatory response following ischemic brain injury. The injured
cells of the CNS, in combination with glial cells which become activated after a stroke,
express chemotaxic molecules that signal to the peripheral immune system that there is
an injury to the brain. Various cytokines cause up regulation of vascular adhesion
molecules in endothelial cells and on immune cells. This creates a leaky BBB which
allows entry of immune cells into the brain (de Vries et al. 1997).

Cells of monocytic origin, CD11b+ cell, become activated as early 18 h and are
significantly increased in number out to 96 h post tMCAO in mice (Stevens et al. 2002).
It is not possible to determine the difference between microglia and peripheral
monocytes/macrophages, as both types of cells express CD11b. Microglia/macrophages
become maximally activated in the brain 72 h post pMCAO in rats (Leonardo et al.
2010). Neutrophils are significantly increased in the infarcted hemisphere beginning 48 h
and remain elevated out to 96 h post tMCAO. As expected with an adaptive immune
response T cells, CD3+ cells, are present in the brain starting 72 h and remain at 96 h
post tMCAO (Stevens et al. 2002).
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There is strong experimental evidence that peripheral immune cells, particularly
lymphocytes, play a role in enhancing neural injury after an ischemic stroke. Following
tMCAO, Rag-/- mice which lack functional T or B cells have decreased infarct volumes
compared to wild type (WT) mice. T cell-/- mice, both CD4-/- and CD8-/-, have decreased
infarct size compared to WT mice. However B cell-/- mice had infarcts similar to WT mice
indicating B cells play a minimal role in detrimental post stroke brain inflammation
(Yilmaz et al. 2006). Additionally, severe combined immunodeficiency (SCID) mice,
which lack lymphocytes, also have reduced infarcts compared to WT mice. SCID mice
also have reduced cytokine levels, except for interleukin 1β (IL-1β), in the brain post
tMCAO (Hurn et al. 2007). T cells that are primed to react with a pro-inflammatory
response to myelin oligodendrocyte glycoprotein (MOG) prior to tMCAO increased
infarct volumes in mice (Ren et al. 2012) or resulted in death following sensitization with
myelin basic protein (MBP) prior to tMCAO in rats (Becker et al. 1997) compared to
animals primed with a non-neural neutral antigen. However, T cells that are tolerized to
MBP prior to tMCAO have decreased infarct volume compared to controls (Becker et al.
1997). The reaction of the immune system towards neural antigens, which is
orchestrated by Th cells, can be harmful or beneficial following ischemic stroke.

Humoral Response
Cytokines have been extensively studied following experimental stroke and in stroke
patients. Most of the data regarding cytokines and stroke have been contradictory, as
some cytokines have dual roles in the immune response and can be protective or
detrimental depending on the circumstances. Some cytokines can be inflammatory early
after a stroke, but provide trophic support to cells at delayed time points. Other cytokines
can have survival or inflammatory effects depending on the receptor to which they bind.
Additionally, some cytokines are elevated very early following stroke. All the above
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stated examples demonstrate why no good therapeutic targets for cytokines have been
developed.

In mouse models of tMCAO, TNFα, IL-1β, and IL-10 have elevated mRNA levels 6 h
post tMCAO (Chang et al. 2011; Offner et al. 2006a). All of these cytokines are elevated
at a time that is outside the therapeutic window to successfully interfere with their
signaling. IL-1β mRNA expression increases early in the brain after an ischemic event
and remains elevated out to 96 h post tMCAO (Chang et al. 2011). IL-1β is expressed by
non immune cells in the brain. Primary producers of IL-1β in the brain are astrocytes and
microglia (de Vries et al. 1997), which could explain why IL-1β is the only cytokine that
does not have decreased expression in SCID mice following tMCAO (Hurn et al. 2007).
IL-10 is considered an anti-inflammatory cytokine and is associated with a Th2 response.
IL-10-/- mice have increase infarct volumes compared to WT mice following tMCAO
(Liesz et al. 2009) and mice that over-express IL-10 have decreased infarct volumes
compared to controls following pMCAO (de Bilbao et al. 2009). This suggests IL-10 may
play a beneficial role following brain ischemia.

TNFα is also expressed early in the brain and is primarily responsible for the activation
of the immune system and recruitment of other immune cells. In addition to being
expressed early, TNFα is known to have different effects following brain ischemia. TNFα
has been shown to exacerbate infarct volume in both tMCAO and pMCAO in a dose
dependant manner (Barone et al. 1997). However, TNFα-/- mice had increased infarct
volumes compared to WT mice following pMCAO (Lambertsen et al. 2009). This
suggests TNFα plays a protective role following ischemic stroke, but when TNFα
converting enzyme (TACE) was inhibited, causing a decrease in TNFα production prior
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to and following pMCAO, TACE-inhibited rats demonstrated decreased infarct volume
and reduced neurological deficits compared to control rats (Wang et al. 2004).

In

addition, blocking TNFα with a neutralizing antibody injected intracerebroventricularly
(i.c.v.) 15 min post tMCAO in mice decreased infarct volume, however, administration of
the same antibody 3 days post tMCAO did not decrease infarct volume (Liesz et al.
2009). TNFα has also been linked to the up regulation of manganese superoxide
dismutase (Mn-SOD), an important anti-oxidant enzyme that is believed to play a role in
ischemic preconditioning in stroke (Hallenbeck 2002). All of the contradictory results in
experimental stroke with TNFα could be due to the two different TNFα receptors and the
subsequent cellular processes induced by these receptors.

The two TNFα receptors, when activated, can result in different cellular responses
depending on the cell type or the presence of both receptors on the same cell. TNFα can
initiate a response resulting in apoptosis and the production of cytokines or be protective
by preventing apoptosis. The two different receptors, TNFαR1 and TNFαR2, result in a
combination of different cellular responses. TNFαR1 has an intracellular death domain
that can divert the cellular response to TNFα in a Fas-associated protein with a death
domain (FADD) towards apoptosis or the binding of TNF-receptor associated protein 2
(TRAP2) which leads to the transcription of anti-inflammatory factors. FADD signals to
activate caspase 8 leading to apoptosis. TRAP2 leads to the activation of NFκB and cJUN which induce anti-apoptotic, anti-inflammatory and cellular protective proteins
(Hallenbeck 2002). TNFαR1 is expressed on all cells, while TNFαR2 is expressed only
on oligodendrocytes, astrocytes, T cells, myocytes, endothelial cells, thymocytes, and
human mesenchymal stem cells. TNFαR2 does not contain an intracellular cytoplasmic
death domain and activation leads to the recruitment of TNF receptor-associated factor 2
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(TRAF2). TRAF2 acts similarly to TRAP2 and activates NFκB, AP1, and mitogenactivated protein kinase (MAPK). The activation of these pathways leads to
inflammation, cellular proliferation, and cell survival (Speeckaert et al. 2012). In pMCAO
experiments with TNFαR knockout mice, TNFαR1-/- was associated with neuroprotection
while TNFαR2-/- was not associated with neuroprotection (Lambertsen et al. 2009).
Studies using cuprizone toxicity as a model of white matter injury found that TNFα is
important in the recruitment of oligodendrocyte progenitors to remyelinate axons. This
TNFα signaling is mediated through the TNFαR2 (Arnett et al. 2001). The diverse effects
of TNFα can be contributed to many factors including timing of TNFα signaling and the
receptors it signals through, and the contradictory outcomes in animal experiments
indicate TNFα is not a good therapeutic target for stroke. Additionally it is initially
elevated outside therapeutically relevant time points to treat stroke.

Another cytokine that has been research extensively in experimental stroke is IL-6. One
of the primary reasons a lot of emphasis has been placed on IL-6 is because it is
detectable in the serum of stroke patients. Serum IL-6 levels in stroke patients have
been shown to be the strongest independent predictive variable of in hospital mortality
following stroke (Rallidis et al. 2006). IL-6 mRNA levels are elevated early in the brain
following tMCAO in mice (Offner et al. 2006a). Despite evidence that IL-6 might be
playing a detrimental role in stroke pathology, there has been very little investigation into
blocking IL-6 as a therapeutic for stroke which is likely due to the confounding data from
animal studies looking at IL-6 and experimental stroke. IL-6-/- mice had infarcts that were
not significantly different than their WT or heterozygous littermates following tMCAO
(Clark et al. 2000). However, IL-6 is known to have pyrogenic activity and IL-6-/- mice
were found to have lower body temperatures compared to WT mice. Body temperature
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is known to play an important role following any brain injury, including stroke. When
IL-6-/- mice had their body temperatures monitored and adjusted to match the WT mice,
the IL-6-/- had significantly increased infarct volumes and increased neurologic deficits
compared to the WT mice following MCAO (Herrmann et al. 2003). An additional study
found i.c.v. administration of recombinant IL-6 prior to pMCAO in rats significantly
decreased infarct volume suggesting IL-6 is directly neuroprotective (Loddick et al.
1998). A different study using IL-6-/- mice found increased infarct volumes compared to
WT mice following tMCAO out to four weeks. This study suggested the loss of IL-6 was
important for angiogenesis during the recovery phase following stroke (Gertz et al.
2012).

One reason for the conflicting experimental data with IL-6 could be due to the multiple
functions of IL-6. Prior to being named IL-6, the 26-kDa protein was named B-cell
stimulatory factor 2, IFN-β2, hybridoma/plasmacytoma growth factor and hepatocyte
stimulating factor along with 26-kDa protein. Once DNA sequencing was completed it
was discovered that all five proteins were the same molecule (Kishimoto 2010). IL-6
signals through one receptor that is a complex of the IL-6R and gp130. The cytoplasmic
domain of gp130 contains several signaling motifs that allow IL-6 to signal through ERK
or Jak1 and STAT3 or STAT1. STAT3 and STAT1 can form homodimers or a
heterodimer once activated. These different signaling pathways allow IL-6 to have
diverse effects on a variety of cells and cellular functions. IL-6 is important for liver
regeneration, angiogenesis, bone, cartilage, and lipid metabolism, iron homeostasis, and
is known to promote cancer cell survival. The immune functions that IL-6 plays a role in
include promoting neutrophil production and recruitment, enhances antibody production
by B cells, and works with transforming growth factor beta (TGFβ) to increase the
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production of pro-inflammatory Th17 cells. Th17 are thought to play a major role in
autoimmune diseases (Mihara et al. 2012). IL-6 plays many different roles following
stroke depending on the exact timing following the stroke, which makes targeting IL-6
after stroke extremely difficult.

Out of numerous studies on cytokines in animals and stroke patients, there has yet to be
a therapeutic developed for stroke. Many cytokines are part of the innate immune
response and increase rapidly following stroke, while other cytokines have dual roles
following stroke or serve a potentially protective function. One cytokine has not been
extensively studied and could have the promise of providing a delayed therapeutic
option that is strictly pro-inflammatory. IFNγ is the signature cytokine of the adaptive
immune Th1 response.

The Importance of Interferon Gamma Signaling following Stroke:
Interferon Gamma and its Receptors
IFNγ is a pleiotropic cytokine that can affect cellular processes ranging from immune cell
function to playing a role in vascular leukocyte adhesion. The 34-kDa homodimer is the
biologically active form of IFNγ (Boehm et al. 1997). The half-life of IFNγ in the blood is
1.1 min if it is not bound to heparin or heparin sulfate, and when bound the half-life is
increased to 99 min. When IFNγ is injected into the bloodstream, 90% of the protein is
proteolytically cleaved at the carboxyl-terminal within 5-10 min rendering it inactive. The
other 10% becomes bound to a heparin molecule, increasing its half-life (Lortat-Jacob et
al. 1996). The biologically active form of IFNγ binds to the IFNγ receptor complex that is
comprised of two pairs of transmembrane proteins which signal through the Janus
kinases (Jaks), and signal transducers and activators of transcription (STATs). Of the
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two different proteins that make up the IFNγ receptor, the IFNγR1, or the α-chain, is the
part of the receptor that binds IFNγ. Following binding of IFNγ the α-chain dimerizes with
another α-chain. Then, the second protein IFNγR2 or the β-chain dimerizes with another
β-chain to the complex. The β-chain is primarily involved in signaling, whereas the αchain is primarily involved in binding IFNγ. Jak1 is associated with the α-chain and Jak2 is
associated with the β-chain. Once IFNγ binds, the Jaks become phosphorylated and
phosphorylate STAT1α that homodimerizes and translocates to the nucleus to affect
transcription. The IFNγ receptor is expressed on every cell in the body but its density
varies from cell type to cell type with immune cells, monocytes in particular, having the
highest expression.

The primary producers of IFNγ are T cells, CD4+ Th1 cells, CD8+ T cells, and NK cells.
IFNγ production is induced by IL-12, IFNα, and even by IFNγ through positive feedback.
IFNγ induces the production of more IL-12 by macrophages which further increase IFNγ
production. In addition to increasing its own expression, IFNγ causes increased
expression of proteins involved in the generation of reactive oxygen species (ROS),
chemotaxis of more immune cells to the site of injury, up regulation of MHC molecules,
and induces isotype switching in B cells. Indirectly, there is also an increase in cellular
adhesion molecules on endothelial cells by IFNγ through up regulating chemokines,
including monocyte chemoattractant proteins (MPCs), monokine induced by gamma
interferon (MIG), interferon-inducible protein 10 (IP-10), IL-8, and interferon-inducible T
cell α chemoattractant (I-TAC). With the recruitment of additional immune cells to the site
of injury, IFNγ also primes T cells and cells of monocytic origin towards a proinflammatory phenotype. IFNγ and its effector molecules prime naïve Th cells to develop
into Th1 cells, blunting the response of other Th subsets. Microglia/macrophages
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become activated in towards a pro-inflammatory state by the up regulation of ROS
production and MHC II expression. The primary role IFNγ plays in the immune response
is to increase resistance to bacteria and viruses, particularly against intracellular
pathogens. To obtain this immune response, the primary target cells of IFNγ in the
immune system are macrophages. These cells are also the primary producers of all the
chemokines like IP-10, MIG, and I-TAC.

The Detrimental Role of IFNγ following Ischemic Brain Injury
There are several data in animals and stroke patients indicating IFNγ plays a detrimental
role in stroke pathogenesis. IFNγ mRNA is up regulated 2 days post pMCAO in the brain
of rats (Li et al. 2001). Additionally, IFNγ-/- mice have decreased infarcts compared to WT
mice and the IFNγ-/- mice infarcts are comparable to Rag-/- mice (Yilmaz et al. 2006).
Delayed administration of antibodies directed against IFNγ decreased infarct volume
when injected i.c.v. 3 days, but not early, post tMCAO (Liesz et al. 2009). In addition,
indirect blocking of IFNγ is neuroprotective. Administration of an anti CD49d (VLA-4)
antibody 24 h prior to the MCAO reduced infarct volume and blocked T cells and NK
cells from entering the brain following tMCAO. This prevented IFNγ producing cells from
entering the injured brain, decreased IFNγ levels and infarct volume (Liesz et al. 2011).
In stroke patients that developed an infection, particularly pneumonia, within 15 days of
having a stroke had a worse outcome compared to individuals that did not develop an
infection, regardless of stroke severity. Individuals that developed an infection were
more likely to have a Th1 response to myelin basic protein (MBP) and glial acid fibrillary
protein (GFAP) at 90 days post stroke, and individuals that generated a higher Th1
response to MBP at 90 days were more likely to have a poorer outcome regardless of
age or baseline stroke severity (Becker et al. 2011). As IFNγ is considered a signature
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cytokine of a Th1 response, this could implicate IFNγ as being detrimental following
stroke in patients when an inflammatory T cell response is generated against brain
antigens.

The Generation of an IFNγ Driven Response to Brain Antigens following Stroke
IFNγ levels in the spleen and in the brain could become increased due to the elevated
levels of circulating catecholamines. Increased levels of circulating norepinephrine (NE)
and epinephrine have been found in humans and rats after they experience a blockage
of the MCA (Meyer et al. 2004; Cechetto et al. 1989). The additional amount of
circulating CAs has been attributed to insular cortex damage, which is mainly perfused
by the MCA. Damage to this region in patients has also been shown to cause
sympathetic dysregulation (Meyer et al. 2004). Furthermore, NE reduces the ability of
Th1 cells to respond when activated, and this effect is thought to be mediated by the
presence of β2 adrenergic receptors on Th1 cells (Sanders et al. 1997). However, naïve
T cells also express β2 adrenergic receptors. When naïve T cells are exposed to NE,
these cells are driven to differentiate into the Th1 phenotype. Upon reactivation, these
cells express 2-4 fold more IFNγ than naïve T cells not exposed to NE (Swanson et al.
2001). This effect of NE on naive T cells and Th1 cells may account for the immune
dysfunction to pathogens and the increased levels of IFNγ production observed in the
spleen following MCAO.

In addition, the cells which are becoming activated in the presence of catecholamines
are also being exposed to brain derived antigens that enter circulation following stroke
(Herrmann et al. 2000; Wunderlich et al. 1999). This could lead to a Th1 response to
brain antigens, which has been shown in animal studies to result in a more severe injury
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(Becker et al. 2005). This may also be mediated through IFNγ, as IFNγ is considered an
initiator of a Th1 response.

Interferon Gamma and the Splenic Response following Cerebral Ischemia
Interferon gamma and the spleen both have the potential to play important roles in
exacerbating neural injury following ischemic stroke. The splenic response does
contribute to increased neural cell death following brain injuries. Additionally,
experiments have measured early IFNγ mRNA levels following experimental stroke in
animals, however, no experiments have been conducted to address whether IFNγ
protein expression is increased following ischemic stroke. Therefore, the first set of
experiments were designed to test the following hypotheses: 1) increased levels
of IFNγ protein are found in the brain and the spleen following pMCAO, and 2) this
increased level of IFNγ protein in the brain is connected to the increased levels
found in the spleen and this increases neural injury.

Splenectomy experiments have demonstrated that the splenic response to brain injuries
is detrimental. Studies using stem cells to treat experimental stroke have shown that
stem cells, including neural stem cells, are more efficacious when administered
systemically compared to local administration. These cells have also been found in the
spleen following systemic administration and that the spleen is necessary for these cells
to exert all their protective effects. The spleen is a major reservoir of immune cells and
peripheral immune cells have been found in the brain following stroke. The second set
of experiments were designed to test the following hypotheses: 1) labeling
splenocytes in vivo prior to pMCAO will allow these cells to be tracked after
pMCAO, 2) labeled splenocytes are found in the brain following pMCAO, and 3)
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the splenocytes in the brain will be contributing to exacerbating neural injury
directly or indirectly by influencing the environment within the infarct.

IFNγ is known to induce several proteins, many of which are chemokines. IP-10 is of
particular interest as it plays a role in influencing the differentiation of naïve Th cells to
become Th1 cells and is a strong chemoattractant for Th1 cells while subsequently
blocking the activation of Th2 cells. The recruitment of more pro-inflammatory Th1 cells
would result in more IFNγ production and further activation of microglia/macrophages.
This would create a feed-forward inflammatory environment in the stroke-injured brain.
Blocking or interfering with IFNγ signaling could provide a targeted approach to blunting
just the pro-inflammatory response and not the whole immune response that is seen with
broad immunosuppressants, like cyclosporine. The final set of experiments were
designed to test the hypotheses: 1) systemic administration of an IFNγ
neutralizing antibody 6 h post pMCAO will decrease infarct volume, 2) treatment
with a neutralizing antibody against IFNγ will decrease the levels of IP-10 the brain
and spleen, and 3) decreased levels of IP-10 will blunt the pro-inflammatory
response in the brain by decreasing the number of T cells recruited to the brain
following stroke.
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Note to Reader
The contents of this section have been previously published (Seifert et al. 2012b) and
are utilized with permission of the publisher.

Abstract
Delayed neuronal death associated with stroke has been increasingly linked to the
immune response to the injury. Splenectomy prior to middle cerebral artery occlusion
(MCAO) is neuroprotective and significantly reduces neuroinflammation. The present
study investigated whether splenic signaling occurs through interferon gamma (IFNγ).
IFNγ was elevated early in spleens but later in the brains of rats following MCAO.
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Splenectomy decreased the amount of IFNγ in the infarct post-MCAO. Systemic
administration of recombinant IFNγ abolished the protective effects of splenectomy with
a concurrent increase in IFNγ expression in the brain. These results suggest a role for
spleen-derived IFNγ in stroke pathology.
Introduction
Current clinical and animal research has shown a complex interplay between the
peripheral immune system and the progression of stroke-induced neurodegeneration.
The brain communicates with the immune system largely via direct innervation of the
lymphoid tissues and humoral control provided by the hypothalamic-pituitary-adrenal
axis (Chrousos 1995).

The spleen is a mediator of the immune response to ischemic injury in all organ systems
examined. Splenectomy reduces the ischemic-induced immune response in the liver
(Okuaki et al. 1996), gastrointestinal system (Savas et al. 2003), kidney (Jiang et al.
2007) and brain (Ajmo et al. 2008). These reports indicate that the presence of the
spleen is necessary for promotion of the inflammatory response to ischemic injury which
is responsible for delayed cellular death.

Splenectomy two weeks prior to middle

cerebral artery occlusion (MCAO) in the rat significantly reduces infarct volume with a
concomitant decrease in the number of immune cells within the infarct (Ajmo et al.
2008). The inflammatory signal from the spleen to the ischemic brain or other organs
has yet to be identified.

Many studies have attempted to decipher the immune signature for an inflammatory
response to stroke (Offner et al. 2006; Liesz et al. 2009a; Ren et al. 2010; Becker et al.
2005).

Many different gene knockout models of inflammatory cytokines have been
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characterized in the field of stroke showing various degrees of increased neuronal death
or protection (Lucas et al. 2006; Boutin et al. 2001). One study reports that the deletion
of the interferon gamma (IFNγ) gene decreases brain damage after MCAO (Yilmaz et al.
2006). Moreover, when IFNγ neutralizing antibodies are infused intraventricularly three
days post-MCAO this protects the brain from stroke induced injury (Liesz et al. 2009b).
Also, mice with increased levels of brain IFNγ as a result of over-expression in
oligodendrocytes (OL), have increased infarcts compared to wild-type mice (Lambertsen
et al. 2004). IFNγ is associated with the Th1 inflammatory response by activating cells of
the

monocytic

lineage,

microglia

and

macrophages.

Since

activation

of

microglia/macrophages is partly responsible for the delayed cellular damage after
ischemic insult, this cytokine could play a role in the splenic response by exacerbating
the inflammation associated with ischemic injury.

In the present study, we examined the expression of IFNγ after MCAO. We discovered
that splenectomy reduced IFNγ expression in the brain after MCAO and that systemic
administration of IFNγ reversed the protective effects of splenectomy. These findings
indicate that IFNγ may be one of the inflammatory signals originating from the spleen
causing a delayed inflammatory response in the ischemic brain.

Materials and Methods
Animal Care
All animal procedures were conducted in accordance with the NIH Guide for the Care
and Use of Laboratory Animals with a protocol approved by the Institutional Animal Care
and Use Committee at the University of South Florida. Male Sprague-Dawley rats (300350g) were used for the in vivo experiments. Postnatal day 3 (P3) rat pups from untimed
pregnant female rats were used for in vitro primary oligodendrocyte cell culture
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experiments and prenatal day 18 (E18) rat embryos from timed pregnant females were
used for in vitro primary neuron cell culture experiments. All rats were purchased from
Harlan Labs (Indianapolis, IN), maintained on a 12 h light/dark cycle (6 am – 6 pm) and
given access to food and water ad libitum.

Splenectomy
Splenectomies were performed two weeks prior to MCAO by making a midline skin
incision at the caudal terminus of the 13th rib on the anatomical left. The abdominal wall
was opened along midline and the spleen was externalized through the incision with
blunt forceps. The splenic blood vessels were ligated and the spleen was removed. The
incision was then closed with sutures, first closing the abdominal cavity and then the skin
incision. Sham operations were also performed where the spleen was exteriorized and
then reinserted into the cavity.

Laser Doppler Blood Flow Measurement
Laser Doppler was used to monitor blood perfusion (Moor Instruments Ltd, Devon,
England). A hole was drilled into the right parietal bone (1 mm posterior and 4 mm lateral
from Bregma), and a guide screw was set. The probe was inserted into the guide screw,
and the tip of the probe was placed against the pial surface of the brain. Rats that did not
show ≥ 60% reduction in perfusion during MCAO were excluded from the study (Ajmo et
al. 2006; Ajmo et al. 2008; Hall et al. 2009a)

Permanent Middle Cerebral Artery Occlusion
MCAO surgery was performed using the intraluminal method originally described by
Longa et al. (Longa et al. 1989) and previously reported (Ajmo et al. 2006; Ajmo et al.
2008; Hall et al. 2009a). Briefly, rats were anesthetized, the common carotid artery
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was separated from the vagus nerve, and blunt dissection was performed to isolate the
internal carotid artery (ICA), and the external carotid artery (ECA). A 40 mm
monofilament was introduced into the ECA, fed distally into the ICA, and advanced
approximately 25 mm through the Circle of Willis to the origin of the middle cerebral
artery. The filament was tied off at the internal/external carotid junction to produce
permanent occlusion. The incision was then sutured closed and the rat was allowed to
wake in a fresh cage. Following recovery, animals were randomly assigned into
treatment groups.

Recombinant IFNγ Administration
Naïve rats were given increasing doses of rIFNγ until an observable physiological
response occurred to determine the optimal rIFNγ dosage. A physiological response to
the rIFNγ was determined by the presence of several characteristics: pilo erection,
excessive porphrin production, lethargy, and chills or fever. The rats were monitored
every 15 min for 2 h following i.v. injections. The dosage of 20 μg was the lowest dosage
which elicited a physiological response and was used to determine the effects of IFNγ on
neural injury in splenectomized and sham-splenectomized rats.

The animals were

injected intravenously (i.v.), via the tail vein, at 48 and 72 h post-MCAO with 0.21 ml of
either 20 μg (in ddH2O) of recombinant IFNγ (rIFNγ) (Prospec, Rehovot, Israel) or 0.21
ml ddH2O.

Brain Extraction and Sectioning
The animals were euthanatized with ketamine/xylazine mix, 75 mg/kg and 7.5 mg/kg
respectively, intraperitoneal (i.p.) at 3, 24, 48, 51, 72 and 96 h post-MCAO, and perfused
transcardially with 0.9% saline followed by 4% paraformaldehyde in phosphate buffer.

41

The brains were harvested, post fixed in 4% paraformaldehyde, and immersed in 20%
followed by 30% sucrose in phosphate buffered saline (PBS). Brains were frozen and
sliced into 30 μm sections with a cryostat. Coronal brain sections were taken at six
points from 1.7 to -3.3 mm from Bregma. Sections were either thaw mounted on glass
slides or placed in Walter’s Anti-freeze cryopreservative and stored at -20°C.

Fluoro-Jade Staining
Slides were stained with Fluoro-Jade, which labels degenerating neurons. This method
was adapted from that originally developed by Schmued et al. (Schmued et al. 1997)
and has been described by Duckworth et al. (Duckworth et al. 2005). Slides were dried,
placed in 100% ethanol for 3 min, 70% ethanol for 1 min, and then ddH2O for 1 min.
Slides were oxidized using a 0.06% KMnO4 solution for 15 min followed by three 1 min
rinses with ddH2O. Slides were stained in a 0.001% solution of Fluoro-Jade (Histochem,
Jefferson, AR) in 0.1% acetic acid for 30 min. Slides were rinsed 4 times with ddH2O for
3 min, allowed to dry at 45oC for 20 min, cleared with xylene and then cover slipped with
DPX mounting medium (Electron Microscopy Sciences, Ft. Washington, PA).

Infarct Volume Quantification
Fluoro-Jade stained tissue was digitally photographed with Zeiss Axioskop2 (Carl Zeiss
INC, Thornwood, NY) microscope controlled by Openlab software (Improvision,
Waltham, MA) at a magnification of 1x. Area of neurodegeneration was measured using
the NIH ImageJ software. The area of the contralateral side of the brain was also
measured and used to compensate for possible edema in the ipsilateral hemisphere.
Infarct volumes were then calculated by the total area of ipsilateral staining divided by
the total contralateral area for a given animal. Infarct quantification was only done at
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96 h post-MCAO because this has been shown to be the time point at which the infarct
is stable (Newcomb et al. 2006).

Immunohistochemistry in the Brain
The slides were dried at 45oC for 1 h then rinsed with PBS pH 7.4. Endogenous
peroxidase activity was extinguished by incubating the slides for 20 min in 3% hydrogen
peroxide. Slides were placed in permeabilization buffer containing 10% serum, 3% 1M
lysine, and 0.3% Triton X-100 in PBS for 1 h at room temperature. Next, sections were
incubated overnight at 4°C in a primary antibody solution (PBS with 2% serum and 0.3%
Triton X-100) in a humidified chamber. Slides were subsequently washed with PBS and
incubated with a secondary antibody solution (PBS, 2% serum, 0.3% Triton X-100) for
1 h. For staining with metal-enhanced 3, 3’-diaminobenzidine (DAB) visualization
sections were washed in PBS (3 x 5 min) following secondary antibody solution and
incubated in an avidin/biotin/horseradish peroxidase complex (Vectastain Elite ABC kit;
Vector Laboratories, Burlingame, CA) for 1 h at room temperature. Sections were
washed in PBS, and DAB (Pierce, Rockford, IL) was used for color development. Slides
were washed thoroughly with PBS and dried for 1 h at 45°C then dehydrated, rinsed with
xylene and cover slipped using DPX (Electron Microscopy Sciences).

For fluorescence staining, the same procedure was followed up to the incubation with
the secondary antibody, though sections were not incubated in hydrogen peroxide.
Slides were washed with PBS after secondary incubation and then cover slipped using
Vectashield hard set mounting media with DAPI (Vector Laboratories). Slides were
protected from light during these steps. Double-labeled immunohistochemistry, for IFNγ
and immune cell surface markers, was achieved by co-incubating the slides with
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primary antibodies raised in two distinct species, followed by co-incubation with
secondary antibodies conjugated to distinct fluorophores.
The following primary antibodies were used: goat anti-rat IFNγ (1:200; R&D Systems,
Minneapolis, MN), mouse anti-rat CD3 for T cells (1:2,000; BD Biosciences, San Jose,
CA), mouse anti-rat CD161 for NK cells (1:1,000; Serotec, Raleigh, NC), mouse anti-rat
CD45R for B cells (1:5,000; BD Biosciences), and mouse anti-rat CD11b for
microglia/macrophages (1:3,000; Serotec). Horse anti-goat biotinylated antibody (1:300;
Vector Laboratories) and Alexa-Fluor® 594 rabbit anti-goat (1:300; Invitrogen, Carlsbad,
CA) secondary antibodies were used with the IFNγ antibody. Alexa-Fluor® 488 rabbit
anti-mouse (1:300; Invitrogen) secondary was used in conjunction with all other
antibodies noted above.

IFNγ Immunohistochemistry in the Spleen
Spleens were fixed in 4% paraformaldehyde overnight. The spleens were then placed in
a solution of 20% glycerol and 2% dimethyl sulfoxide (DMSO) and embedded in a
gelatin matrix using MultiBrain Technology© (NeuroScience Associates, Knoxville, TN).
The block of spleens was rapidly frozen in isopentane with crushed dry ice (-70°C).
Using a microtome the block was sliced into 25 µm sections. Six consecutive sections
were taken and collected in Antigen Preservation solution (50% ethylene glycol, 49%
PBS pH 7.0, 1% polyvinyl pyrrolidone). The spleen sections were stained free floating in
Tris-buffered saline (TBS) solutions. Endogenous peroxide activity was extinguished by
treatment with 3% hydrogen peroxide for 15 min. After washing with TBS sections were
incubated for 30 min in permeabilization buffer (TBS with 0.3% TritonX-100 and 10%
rabbit serum). Following permeabilization, slides were incubated overnight at room
temperature with primary antibody in TBS with 2% rabbit serum. The sections were
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rinsed with TBS and incubated in secondary biotinylated antibody in TBS with 2% rabbit
serum for 1 h. After being rinsed with TBS, sections were incubated with an
avidin/biotin/horseradish peroxidase complex (Vectastain Elite ABC kit) for 1 h. Staining
was visualized with DAB (Sigma-Aldrich, St. Louis, MO). The sections were then
mounted on gelatinized slides, dried, dehydrated, cleared with xylene, and cover slipped
with Permount (Fischer Scientific, Pittsburg, PA). The primary antibody used was goat
anti-rat IFNγ (1:1,500; R&D Systems,) and the secondary antibody was biotinylated
rabbit anti-goat (1:256; Vector Laboratories,).

IFNγ Immunohistochemistry Quantification
IFNγ stained tissue sections were digitally photographed with Zeiss Axioskop2 (Carl
Zeiss INC, Thornwood, NY) microscope controlled by Openlab software (Improvision,
Waltham, MA) at a 10x magnification. One image from each Bregma point was taken for
a total of six images per brain. The area selected for quantification was from the periinfarct region of the ipsilateral hemisphere for all animals. The images were analyzed for
percent of immunostaining per area with ImageJ software. These six values were then
averaged for each brain.

Splenic images were taken with a Nikon 90i microscope using a 20x objective and NIS
Elements BR 2.30 software at a high resolution. The images were processed and
analyzed with Photoshop CS5 (Adobe Systems Inc., San Jose, CA). The intensity of the
staining was measured in the histogram for the entire image and the amount of staining
per image was analyzed. Six sections per spleen were analyzed for each rat.
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Neuronal Cultures
Cortices from E18 rat embryos were dissociated with a solution of 0.25% trypsin/2.21mM
EDTA for 10 min at 37°C. The solution was triturated to obtain a uniform single cell
suspension. Then 40 ml of DMEM (Mediatech, Manassas, VA) was added and the
solution was allowed to settle. The supernatant was transferred to a fresh conical tube
and centrifuged at 1000 rpm for 10 min. The supernatant was aspirated off, the pellet
was re-suspended in DMEM and the solution was allowed to settle. The debris from the
bottom was removed with a pipette and the solution was centrifuged for 10 min at 1000
rpm. The supernatant was aspirated off and the cells were re-suspended in DMEM.
Trypan blue exclusion was used to count viable cells and 3x105 cells in a final volume of
1 ml were plated in 24 well poly-L-lysine treated culture plates. Twenty-four hours later
the media was changed to neurobasal complete (neurobasal media (Invitrogen), B-27
(Invitrogen), 0.05 mM L-glutamine (Mediatech)) for seven days. After a media change,
the cells were used for oxygen glucose deprivation (OGD) experiments.

Mixed Glial Cultures
A 2.21mM EDTA solution containing 0.25% trypsin was used to dissociate cortices from
P3 rat pups. The suspension was triturated and pelleted. The pellet was re-suspended in
DMEM+, which consisted of DMEM (Mediatech), 2.5% fetal bovine serum, 10% horse
serum, and 1% antibiotic/antimycotic (Mediatech). After Trypan Blue exclusion to assess
cell viability, cells were seeded at a concentration of 1.5x107 cells in 75 cm2 poly-L-lysine
treated tissue culture flasks. The following day the media was changed to fresh DMEM+
and the cultures were incubated at 37°C for 8 days (Gottschall et al. 1995; Rowe et al.
2010).
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Oligodendrocyte Purification
To separate the microglia cell fraction from the OL/astrocyte monolayer, flasks were
mechanically shaken for 1 h and the media was discarded. Fresh DMEM+ was added to
the flasks and incubated for 2 days at 37°C. Following the 2 day incubation, the flasks
were mechanically shaken for 18 h to remove the astrocytes from the OLs and microglia.
The media was collected and cells were pelleted and re-suspended in fresh DMEM+.
Trypan Blue exclusion was used to count the viable cells. The media containing OLs and
microglia was added to 10 cm plastic tissue culture dishes at a concentration of 107
cells/dish and incubated for 15 min at 37°C. This was repeated three times to assure
microglial adherence to the plastic. Following the final incubation the dishes were gently
agitated and the media was removed. The cells were pelleted, re-suspended in DMEM+,
and plated on poly-L-lysine treated glass coverslips at a concentration of 3x105
cells/coverslip (McCarthy and de Vellis 1980). After 24 h the media was changed to
neurobasal complete with 10 ng/ml of platelet derived growth factor-AA (PDGF-AA)
(Barres et al. 1993; Yang et al. 2005) and the OLs were allowed to proliferate for 7 days.
Afterwards, the PDGF-AA was withdrawn for 5 days allowing the OLs to progress to the
mature phenotype (Yang et al. 2005). All experiments were conducted on cultures
following the 5 day PDGF-AA withdrawal and all cultures used for experiments were
95% pure OLs (Hall et al. 2009b; Rowe et al. 2010).

Oxygen Glucose Deprivation and rIFNγ Administration
Mature OLs that were seeded on glass coverslips in 6 well culture plates were subjected
to 24 h of OGD. Neurons that were seeded in 24 well culture plates were subjected to
either OGD or normoxia for 24 h. OGD conditions were induced using DMEM without
glucose and placing the cultures in an air tight chamber that was flushed with hypoxic
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gas (95% N2, 4% CO2, and 1% O2; Airgas, Tampa, Fl) for 15 min and sealed for 24 h at
37°C. Cultures exposed to normoxia were incubated in DMEM with glucose in a
standard tissue culture incubator for 24 h at 37°C. The two groups were further divided
into cultures that received 20 ng/ml of rIFNγ or vehicle just prior to the

24 h OGD or

normoxic conditions. The concentration of 20 ng/ml of rIFNγ was previously shown to kill
immature oligodendrocytes but not mature OLs (Horiuchi et al. 2006).

Lactate Dehydrogenase Assay
The amount of neuronal and OL cell death was determined using a lactate
dehydrogenase (LDH) assay (Takara Bio, Inc, Madison, WI). Following 24 h of OGD or
normoxia, the culture media was removed and centrifuged. Then 100 µl of media was
added to 100 µl of LDH reagent and incubated in a 96 well plate for 30 min at room
temperature protected from light. The plate was then read at 548 nm on the μQuant
platereader (Bio-tek, Winooski, VT).

Statistical Analysis
All data are expressed as group mean ± SEM. Significance of the data was determined
by ANOVA with a Dunnet’s post hoc test for IFNγ immuno-staining in the brain and
neuronal culture survival. Following ANOVA, a Bonferroni’s post hoc test was used for
the rIFNγ splenectomy treatment groups. A Tukey’s post-hoc test was used following
ANOVA to determine significance for the splenic IFNγ protein levels. A two tailed t-test
was used to for OL survival in culture. A value of p<0.05 was considered significant. All
sections were blinded prior being analyzed by an investigator.
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Results
IFNγ Levels are Increased in the Brain following MCAO
To determine if IFNγ is present in the brain following MCAO, its expression in the infarct
was characterized over time. To quantify IFNγ levels, immunohistochemistry for IFNγ
was performed on brain sections from sham operated animals and from animals
euthanized at 3, 24, 48, 72, and 96 h following MCAO. IFNγ protein levels were
significantly increased at 72 h (p<0.01) and remained elevated at 96 h (p<0.05)
compared to sham operated rats 96 h after surgery (Fig. 1). Immunohistochemistry was
also performed on brain sections from rats that received splenectomy two weeks prior to
MCAO and were euthanized at 72 and 96 h post-MCAO. Splenectomy decreased IFNγ
protein levels down to those not significantly different from sham MCAO at both 72 and
96 h post-MCAO. Additionally splenectomy reduces IFNγ protein levels significantly at 72
h compared to 72 h post-MCAO only and as well as at 96 h when compared to 96 h
post-MCAO only.

IFNγ Protein Levels in the Spleen are Elevated at 24 h following MCAO
Splenic production of IFNγ was measured by immunohistochemical analysis of the
spleen. IFNγ protein levels were significantly elevated at 24 h post-MCAO compared to
48, 72, and 96 h post-MCAO, and also elevated compared to the sham-operated rats at
48 and 96 h after surgery (p<0.0002). Naïve spleens showed very low levels of IFNγ
protein expression (Fig. 2).

IFNγ Expression by T Cells, NK Cells, and B Cells in and around the Infarct
Immunostaining for IFNγ was abundant in the infarct of rat brains at 96 h post-MCAO
(Fig. 3A). Double staining with antibodies against immune cell markers and IFNγ showed
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co-localization of CD3 (T cells) (Fig. 3B), CD161 (NK cells) (Fig. 3C), and CD45R (B
cells) (Fig. 3D) with IFNγ. These results indicate T cells, NK cells and B cells were
producing IFNγ in and around the infarct. CD11b positive cells did not co-localize with
IFNγ staining cells, indicating that microglia/macrophages were not producing IFNγ (Fig.
3E).

T cells, B cells, NK cells, and Microglia/Macrophages are Present in the Ipsilateral
Hemisphere following MCAO
Antibodies directed against immune cell surface markers showed that T cells (CD3), NK
cells (CD161), B cells (CD45R), and microglia/macrophages (CD11b) are localized in
the infarcted area of the ipsilateral hemisphere 96 h following MCAO (Fig. 4A-D). In
splenectomized rats, there was a decrease in the immunostaining for T cells, NK cells,
and B cells in the injured hemisphere (Fig. 4E-G). Microglia/macrophages in the infarct
declined in the ipsilateral hemisphere of splenectomized rats (Fig. 4H).

In

splenectomized rats the predominant form of microglia/macrophages appear with an
amoeboid morphology but these cells still display evident ramifications in the damaged
area. Only microglia in the resting, ramified morphology were present in the contralateral
hemispheres (Fig. 4I-L).

Administration of rIFNγ following MCAO Abolishes the Protective Effect of
Splenectomy
IFNγ production originating from the spleen could contribute to delayed neural death and
explain why splenectomy prior to MCAO is neuroprotective. To test this, rats underwent
splenectomy or sham-splenectomy two weeks prior to MCAO. Animals were then
administered rIFNγ (20 μg/rat i.v.) or ddH2O at 48 and 72 h post-MCAO. Infarct volumes,
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as measured by Fluoro-Jade staining, at 96 h post-MCAO showed splenectomized rats
that received systemic rIFNγ had infarcts that were significantly greater than
splenectomized vehicle rats (p<0.0001). The splenectomized rIFNγ rats had infarcts that
were not significantly different from either of the sham-splenectomized rat groups (Fig.
5E). There was an average of 5% infarct in the splenectomy vehicle brain sections (Fig.
5C), compared to the average infarcts of (50-70%) for all other treatment groups (Figs.
5A, 5B, and 5D).

Recombinant IFNγ Increases IFNγ Expression in the Infarct of Splenectomized
Rats
Immunohistochemical analysis for IFNγ in the brain was performed to determine the
effect of rIFNγ administration on levels of this cytokine in the infarct. IFNγ expression
was significantly decreased in the infarct of splenectomized-vehicle rats (Fig. 6C)
(p<0.02) compared to all other groups (Fig. 6E). The addition of rIFNγ to splenectomized
rats (Fig. 6D) increased IFNγ protein levels in the infarct to levels found in rats which
underwent sham-splenectomy prior to MCAO (Fig. 6A and B).

Recombinant IFNγ is Not Cytotoxic to Cultured Primary Neurons or OLs
To determine if rIFNγ is directly toxic to neural cells, cultured neurons and OLs were
treated with rIFNγ prior to OGD. Cell death as measured with LDH assays show that
treatment with rIFNγ does not directly enhance death of neurons (Fig. 7A) in culture
under normoxic or OGD conditions. Recombinant IFNγ does not increase the death of
cultured OLs (Fig. 7B) exposed OGD conditions. Representative images of primary
neuronal (Fig. 7C) and primary OL cultures (Fig. 7D) prior to experimentation are
provided.
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Discussion
The spleen is a key component in the immune response to ischemic injury of the brain
and other organs (Okuaki et al. 1996; Savas et al. 2003; Jiang et al. 2007).
Splenectomy is protective in models of ischemic (Ajmo et al. 2008), hemorrhagic (Lee et
al. 2008), and severe traumatic brain injury (Li et al. 2011). Together, these studies
suggest there is a splenic response that exacerbates neural injury by initiating a delayed
inflammatory response.

Notably, IFNγ perpetuates the pro-inflammatory response by promoting Th1 cell
differentiation while inhibiting Th2 cell differentiation. Additionally, it is known to activate
numerous immune cell types including microglia/macrophages, NK cells, B cells, and T
cells, as well as vascular endothelial cells. Furthermore, this pro-inflammatory cytokine
also influences antibody isotype production, up regulates both major histocompatibility
complexes (MHC I and MHC II), induces changes in vascular endothelial cell adhesion,
and increases the production of reactive oxygen species (Boehm et al. 1997). These
actions are detrimental to the survival of compromised neural cells. In particular the
enhanced Th1 response seen with IFNγ has been found to be detrimental in ischemic
brain injuries. A Th1 response to brain antigens has been shown in animal studies to
result in a more severe injury (Becker et al. 2005) and is a poor prognostic factor
regardless of stroke severity in people (Becker et al. 2011).

Experimental data suggest that IFNγ plays an important role in exacerbating neural
injury, as IFNγ knockout mice show reduced infarct volume following transient MCAO
(Yilmaz et al. 2006). In contrast, a different study demonstrated that there was no
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difference in infarct volume between IFNγ knockout and wild type mice following MCAO
(Lambertsen et al. 2004). However, this latter study used a different model of MCAO
from the one used in the Yilmaz study. Increased serum levels of IFNγ have been
detected in mice 24 h following MCAO (Liesz et al. 2009a).

In stroke patients IFNγ production was reduced 6 h following symptom onset. However,
IFNγ expression returns to levels not significantly different than healthy controls 72 h
following symptom onset. In these patients, IFNγ was being produced by the innate cells
of the immune system, specifically γδT cells, NK cells, and natural killer T (NKT) cells
(Peterfalvi et al. 2009). Both animal and human studies provide strong support for IFNγ
and the innate immune system response in the progression of tissue damage in
ischemic brain injury.

Splenic IFNγ protein levels were elevated at 24 h post-MCAO and decrease by 48 h. The
spike of IFNγ found in the spleen of the rats suggests it is being produced by innate
immune cells, in particular NK cells as they are a major source innate IFNγ (Boehm et al.
1997). This transient spike in IFNγ protein expression in the spleen at 24 h is consistent
with rises in IFNγ mRNA in the spleens of mice 22 h following transient MCAO (Hurn et
al. 2007).

Our results indicated an increase in IFNγ protein expression in the injured brain at 72 h
post-MCAO, with expression remaining elevated at 96 h. These results are consistent
with studies examining IFNγ mRNA levels in the brain following MCAO. For example, Li
et al. (2001) demonstrated that IFNγ mRNA increased in the infarct at 2 days postMCAO and remained elevated 6 days following MCAO (Li et al. 2001). Other reports
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have shown that IFNγ mRNA levels were decreased in the mouse brain at 22 h following
MCAO (Offner et al. 2006). An experiment by Liesz et al. (2011) in which mice were
administered an antibody directed against CD49d (VLA-4) 24 h prior to transient MCAO
provides further support for delayed IFNγ production in the brain. Trafficking of T and
NK cells into the brain was decreased in the CD49d antibody treated mice compared to
control mice. In the same experiment there was also a decrease in the amount of IFNγ
mRNA at 72 h post-MCAO in the antibody treated mice compared to the control mice
(Liesz et al. 2011). This experiment suggests that T cells and NK cells are a source of
IFNγ in the brain at later time points following MCAO which is also consistent with our
findings.

The increase in IFNγ expression in the brain at 72 h post-MCAO coincides with the time
point at which microglia/macrophages become maximally activated in the brain
(Leonardo et al. 2010). As IFNγ is a potent activator of microglia/macrophages, the delay
in the activation of these cells in the brain suggests that splenic IFNγ is acting through
other immune cells to elicit this delayed effect to the infarct. A direct systemic IFNγ
response from the spleen would be expected to cause a more immediate response.
Therefore, it is more likely that IFNγ production in the spleen acts on target cells within
the spleen and these cells then migrate to other immune organs to interact with other
cell

types.

These

cells

could

then

infiltrate

the

brain

stimulating

the

microglia/macrophages to degrade the infarcted area in the brain. As T cells and NK
cells have been found in the peri-infarct region producing IFNγ 96 h following MCAO, the
likely sequence of events starts with an initial increase in IFNγ in the spleen leading to
delayed neural injury.
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Our results suggest the neuroprotection resulting from splenectomy is caused by the
loss of IFNγ. Systemic administration of rIFNγ to splenectomized rats resulted in infarct
volumes that were not different from sham-splenectomized rats, suggesting that spleen
derived IFNγ is responsible for the delayed expansion of the penumbra. Interestingly,
sham-splenectomized rats that received rIFNγ did not have larger infarcts than shamsplenectomized rat that received vehicle. This finding suggests the endogenous IFNγ
response from the spleen is enough to cause maximal delayed neural damage following
a stroke.

Splenectomy reduced the amount of IFNγ protein in the brain following MCAO and
administration of rIFNγ restores IFNγ production in the brains of splenectomized animals
to levels seen in sham-splenectomized rats. Additionally IFNγ expression was not
significantly higher in the brains of sham-splenectomy rats that received rIFNγ compared
to rats that received vehicle treatment. This observation provides evidence that the IFNγ
from the spleen has a relationship to the IFNγ produced in the brain following MCAO.
Whether this is a direct (systemic) or indirect (cellular) relationship is yet to be
determined.

As previously reported, splenectomy reduced the number of Isolectin IB4 and
myeloperoxidase (MPO) positive cells, activated microglia/macrophages and neutrophils
respectively, in the infarcted hemisphere 96 h post-MCAO (Ajmo et al. 2008).
Splenectomy reduces the number of peripheral immune cells, specifically T cells, B cells,
and NK cells, in the ipsilateral hemisphere and alters the morphology of
microglia/macrophages responding to the injury at 96 h following MCAO. A majority of
the microglia in the splenectomized rats appear in transitional state with amoeboid-like
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cell body with ramifications, not the completely amoeboid morphology observed in
MCAO only rats at 96 h. As IFNγ activates microglia/macrophages, the lack of this
cytokine would maintain these cells towards a resting state. Therefore, blocking splenic
IFNγ could prove to be a therapeutic option in modulating the immune response
following ischemic stroke.

Experiments with rIFNγ were performed on cell cultures to ensure that the increase in
infarct volume in the splenectomy-rIFNγ group was due to activation of the immune
system and not the result of the rIFNγ being directly cytotoxic to neural cells. A previous
study demonstrated that IFNγ is not cytotoxic to primary mature OLs at 20 ng/ml
(Horiuchi et al. 2006). This concentration was used to treat primary neural cell cultures
under normoxic and OGD conditions. Recombinant IFNγ is not directly cytotoxic to
cultured neurons or OLs demonstrating that other cells through activation by IFNγ, like
microglia, are eliciting their cytotoxic effect. This contention is further supported by (BalPrice and Brown 2001) who showed that IFNγ added to mixed brain cell cultures results
in neuronal cell death. The neurotoxic effects of IFNγ appear to be mediated through the
activation of microglia/macrophages.

From these various experiments, blocking IFNγ from facilitating a pro-inflammatory
response to ischemic stroke is a potential way to reduce injury. Selectively blocking IFNγ
signaling will allow for targeting one facet of the immune response, leaving the antiinflammatory or pro-regenerative facets able to respond to the injury.
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Figure 1:

IFNγ levels increase in the injured brain post-MCAO. IFNγ

immunohistochemistry of brain tissue from sham operated animals, animals that
received splenectomies two weeks prior to MCAO and were euthanized at 72 and 96 h
post-MCAO, and animals 3, 24, 48, 72, and 96 h post-MCAO. IFNγ protein levels were
significantly higher at 72 and 96 h compared to sham operated animals and animals that
received splenectomy prior to MCAO at 72 and 96 h post-MCAO (* p<0.01; # p<0.05).
For each group n ≥ 3. Box in brain graphic depicts area used for quantification of IFN γ
levels. Sham denotes a sham MCAO and Spl denotes rats that underwent splenectomy
prior to MCAO.
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Figure 2: Splenic IFNγ production is elevated at 24 h post-MCAO. Spleens from
animals 24, 48, 72, 96 h post-MCAO along with naïve, 48 and 96 h sham-MCAO were
assayed using immunohistochemistry for IFNγ. IFNγ protein levels were found to be
significantly elevated 24 h post-MCAO (* p<0.0002) compared to the other groups.
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Figure 3: IFNγ expression in immune cells in the brain post MCAO. Representative
brain sections from rats 96 h post-MCAO were stained with IFNγ and immune cell
surface markers to identify what types of cells are expressing IFNγ in the infarct and periinfarct. Micrographs show IFNγ (red) (A), and double staining merged images of IFNγ
(red) with CD3 (green) for T cells (B), CD161 (green) for natural killer cells (C), and
CD45R (green) for B cells (D); yellow cells with white arrows indicate areas of colocalization. A micrograph of staining with CD11b (green) for microglia/macrophages and
IFNγ (red) (E) demonstrate a lack of co-localization of CD11b and IFNγ. In figure e,
arrow heads indicate IFNγ positive cells and yellow arrows indicate CD11b positive cells.
Scale bars = 20 μm. Box in brain graphics depicts the regions where images were taken
for a given micrograph.
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Figure 4:

Differences in immune cell infiltrates in the brain following with

splenectomy. T cells, B cells, NK cells, and microglia/macrophages are present in the
ipsilateral hemisphere following MCAO. At 96 h post-MCAO immunohistochemistry for
immune cell surface markers shows peripheral immune cells are present in the
ipsilateral hemisphere. Micrographs show CD3 positive cells (T cells) (A), CD161
positive cells (NK cells) (B), CD45R positive cells (B cells) (C), and CD11b positive cells
(microglia/macrophages)

(D)

in

the

infarcted

hemisphere.

Micrographs

from

splenectomized rats demonstrate a decrease in immunostaining for T cells (E), NK cells
(F), B cells (G), and microglia/macrophages (H) in the ipsilateral hemisphere. However
in the contralateral hemisphere there is an absence of staining for T cells (I), NK cells
(J), and B cells (K). Only microglia/macrophages were detected in the contralateral
hemispheres (L). Inserts provide representative images of the morphological states of
the microglia/macrophages present in each group and show an amoeboid cell (D), an
amoeboid cell with evident ramifications (H), and a ramified cell (L). Scale bars = 100
µm. The scale bar of the inserts = 20 µm. Box in brain graphics depicts the regions
where images were taken for a given micrograph.
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Figure 5:

Recombinant IFNγ increases neural injury following MCAO in

splenectomized rats. Recombinant IFNγ increases infarct volume in splenectomized
rats at 96 h post-MCAO to levels not different from sham-splenectomized rats. Infarct
volumes were measured as a percentage of the contralateral hemisphere with FluoroJade staining. Graph depicts average infarct volumes for each group at 96 h post-MCAO
(E). The splenectomy-vehicle treated rats had significantly lower infarcts than the other
treatment groups (* p<0.0001). The splenectomy-IFNγ treated rats had infarcts that were
not significantly different from the sham-splenectomy groups. Representative images for
each treatment group at 96 h post-MCAO: sham-splenectomy-vehicle (SS-V) n=4 (A),
sham-splenectomy-rIFNγ (SS-IFNγ) n=6 (B), splenectomy-vehicle (S-V) n=4 (C), and
splenectomy-rIFNγ (S-IFNγ) n=6 (D). Scale bars = 2 mm.

66

Figure 6:

Recombinant IFNγ increases IFNγ expression in the infarct of

splenectomized rats. The graph shows splenectomy results in a significant decrease in
IFNγ protein expression at 96 h post-MCAO (* p<0.02) (E). However rats that received
splenectomy and rIFNγ had IFNγ protein levels not significantly different than the rats
which underwent sham-splenectomy prior to MCAO. Representative images from each
treatment group at 96 h following MCAO: sham-splenectomy-vehicle (SS-V) (A), shamsplenectomy-rIFNγ (SS-IFNγ) (B), splenectomy-vehicle (S-V) (C), and splenectomy-rIFNγ
(S-IFNγ) (D). Box in brain graphics depicts the regions where images were taken for a
given micrograph.
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Figure 7: Recombinant IFNγ is not cytotoxic to cultured primary neurons or OLs.
Primary neuronal and OL cultures were treated with 20 ng/ml of rIFNγ under normoxic
and OGD for 24 h. Recombinant IFNγ does not increase the amount of cell death, as
measured by LDH, in neuronal cultures under normoxic or OGD conditions for 24 h (A).
Oligodendrocytes subjected to 24 h of OGD and rIFNγ did not have significantly different
survival rates (B). Representative images depict neuronal (C) and OL (D) cultures prior
to treatment. Scale bars = 30 µm.
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Chapter 2:
A Transient Decrease in Spleen Size following Stroke Corresponds to Splenocyte
Release into Systemic Circulation
Hilary A. Seifert, M.S.1, Aaron A. Hall, Ph.D.1, Cortney B. Chapman, B.A.1, Lisa A.
Collier, B.S.1, Alison E. Willing, Ph.D.2, and Keith R. Pennypacker, Ph.D.1
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Note to Reader
Portions of this section have been previously published (Seifert et al. 2012a) and are
utilized with permission of the publisher.

Abstract
The splenic response to stroke is a proinflammatory reaction to ischemic injury resulting
in expanded neurodegeneration. Splenectomy reduces neural injury in rodent models of
hemorrhagic and ischemic stroke, however the exact nature of this response has yet to
be fully understood. This study examines the migration of splenocytes after brain
ischemia utilizing carboxyfluorescein diacetate succinimidyl ester (CFSE) to label them
in vivo. The spleen was found to significantly decrease in size from 24 to 48 h following
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middle cerebral artery occlusion (MCAO) in rats compared to sham operated controls.
By 96 h post-MCAO the spleen size returned to levels not different from sham operated
rats. To track splenocyte migration following MCAO, spleens were injected with CFSE to
label cells. CFSE positive cell numbers were significantly reduced in the 48 h MCAO
group versus 48 h sham and CFSE labeled cells were equivalent in 96 h MCAO and
sham groups. A significant increase of labeled lymphocyte, monocytes, and neutrophils
was detected in the blood at 48 h post-MCAO when compared to the other groups.
CFSE labeled cells migrated to the brain following MCAO but appear to remain within
the vasculature. These cells were identified as natural killer cells (NK) and monocytes at
48 h and at 96 h post-MCAO NK cells, T cells and monocytes. At 96 h post-MCAO
CFSE labeled cells are producing interferon gamma. Splenocytes are released from the
spleen following ischemic brain injury, enter into systemic circulation and migrate to the
brain exacerbating neural injury.

Introduction
Stroke is a complex neural injury that progresses through several phases following the
initial insult. The peripheral immune system plays a delayed role in the progression of
neural injury following stroke. The presence of peripheral immune cells in the brain
following ischemic stroke has been well documented in animal studies (Schroeter et al.
1994; Stevens et al. 2002). The role that these cells play in the progression of neural
injury following stroke is still being investigated, as the origin of these cells is not clearly
understood. Recent evidence indicates that the spleen is at least one of the sources of
these immune cells.

70

The spleen is a large reservoir of immune cells and red blood cells. Its removal reduces
neurodegeneration in a variety of brain injury models (Ajmo et al. 2008; Lee et al. 2008;
Li et al. 2011; Das et al. 2011).

Moreover, splenectomy decreases cellular death

following ischemic-reperfusion injury in other organs, including the liver (Okuaki et al.
1996), intestines (Savas et al. 2003), kidney (Jiang et al. 2007), and heart (Leuschner et
al. 2010). Splenectomy also decreases the number of immune cells in the brain (Ajmo et
al. 2008; Seifert et al. 2012) following middle cerebral artery occlusion (MCAO).
Additional studies have shown that preventing peripheral immune cell infiltration is
neuroprotective following MCAO. Antibodies generated against cellular adhesion
molecules prevent immune cell extravasation into the brain and decrease infarct volume
(Chopp et al. 1996; Kanemoto et al. 2002; Liesz et al. 2011). Cytokine production within
the brain following MCAO is also decreased with splenectomy (Seifert et al. 2012).
These studies illustrate that the spleen is a focal point for the immune response to tissue
injury.

In addition to peripheral immune cells being present in the ischemic brain they produce
and secrete proinflammatory cytokines while in the brain. Several cytokines and
chemokines have up regulated mRNA expression in the brain following transient MCAO
in mice. (Chang et al. 2011; Hurn et al. 2007; Offner et al. 2006a) Elevated levels of
interferon gamma (IFNγ) protein have been found in the brain following permanent
MCAO in rats (Seifert et al. 2012). Additionally, intracerebroventricular injection of
antibodies directed against either tumor necrosis factor alpha (TNFα) or IFNγ following
MCAO decreased infarct volume (Liesz et al. 2009). These data demonstrate that the
presence of peripheral immune cells is detrimental following stroke, whether these cells
are acting through a cellular cytotoxic mechanism or through the secretion of
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proinflammatory cytokines and chemokines. Elucidating the source of these cells should
provide some insight into the mechanisms by which these cells elicit a proinflammatory
response following ischemic brain injury.

This study aims to determine temporal changes in splenic mass in rats following MCAO
to determine if splenic contraction leads to an increase in circulating splenocytes. It has
been well documented that there are peripheral immune cells present in the brain hours
to days following MCAO (Stevens et al. 2002), however the origin of these cells remains
to be elucidated. The spleen contributes to the proinflammatory response following
MCAO and is a major reservoir of immune cells. Using carboxyfluorescein diacetate
succinimidyl ester (CFSE), a fluorescent molecule that covalently binds to intracellular
proteins, allowed splenocytes to be tracked in this study. CFSE is used in lymphocyte
trafficking studies in vivo (Weston and Parish 1990) and can be detected for up to 8-10
cell divisions (Lyons 2000). It has also been shown to be detected out to 20 days in
transplanted hepatocytes (Karrer et al. 1992). This suggests CFSE is a stable molecule
that allows cells to be tracked using fluorescence. By labeling splenocytes in vivo with
CFSE prior to MCAO, splenocyte migration was tracked following MCAO.

Materials and Methods
Animal Care
All animal procedures were conducted in accordance with the NIH Guide for the Care
and Use of Laboratory Animals with a protocol approved by the Institutional Animal Care
and Use Committee at the University of South Florida. Male Sprague-Dawley rats (300350g) were used for the in vivo experiments. All rats were purchased from Harlan Labs
(Indianapolis, IN), maintained on a 12 h light/dark cycle (6 am – 6 pm) and given access
to food and water ad libitum.
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Splenic CFSE Injections
Splenic CFSE injections were performed five days prior to MCAO by making a midline
skin incision at the caudal terminus of the 13th rib on the anatomical left. The abdominal
wall was opened along midline and the spleen was externalized through the incision with
blunt forceps. The spleens were injected with 250µl of a 4mg/ml solution of CFSE
(Molecular Probes, Eugene, OR) in dimethyl sulfoxide (DMSO). The injections were
evenly spaced out in five sites of 50µl per site along the spleen. The spleen was then
reinserted into the abdominal cavity. The incision was then closed with sutures, first
closing the abdominal cavity and then the skin incision. To obtain baseline CFSE
labeling, a group of CFSE only rats were euthanized five days following the splenic
injections; at the same time point the other groups underwent MCAO or sham surgeries.

Laser Doppler Blood Flow Measurement
Laser Doppler was used to monitor blood perfusion (Moor Instruments Ltd, Devon,
England). A hole was drilled 1 mm posterior and 4 mm lateral from Bregma, and a guide
screw was placed. The laser doppler probe was inserted into the guide screw, and the
tip of the probe was placed against the surface of the brain. Rats that did not show ≥
60% reduction in perfusion during MCAO were excluded from this study (Ajmo et al.
2006; Ajmo et al. 2008; Hall et al. 2009). Sham operated rats had the guide screw and
laser doppler probe placed and blood flow was monitored to ensure that there was not a
drop in cerebral blood flow during the sham procedure.

Permanent Middle Cerebral Artery Occlusion
MCAO surgery was performed using the intraluminal method originally described by
Longa et al. (Longa et al. 1989) and previously reported (Ajmo et al. 2006; Ajmo et al.
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2008; Hall et al. 2009). Briefly, rats were anesthetized. Then blunt dissection was
performed to isolate the common carotid artery, the internal carotid artery (ICA), and the
external carotid artery (ECA). A 40 mm monofilament was introduced into the ECA, fed
distally into the ICA, and advanced to the origin of the MCA. The filament was tied off on
the ECA to produce a permanent occlusion. The incision was then sutured closed and
the rat was allowed to wake in a fresh cage. Sham operations were performed for the
CFSE rats at 48 and 96 h post-MCAO to ensure there no confounding factors from the
CFSE injections.

Tissue Extraction and Sectioning
The animals were euthanatized with ketamine/xylazine mix, 75 mg/kg and 7.5 mg/kg
respectively, intraperitoneal (i.p.) at 3, 24, 48, 51, 72 and 96 h post-MCAO, and perfused
transcardially with 0.9% saline followed by 4% paraformaldehyde in phosphate buffer
(PB). The spleens and thymi were removed prior to perfusion. Spleens were weighed
immediately following removal and were subsequently placed in RPMI complete (RPMI1640 without Phenol Red media (Cellgro, Manassas, VA), antibiotic/antimycotic
(Cellgro),

29.2

mg/ml

L-glutamine,

low

IgG

FBS

(Cellgro),

and

14.2M

2-

mercaptoethanol) cell culture media. The thymi were placed in 4% paraformaldehyde in
PB. Thymi were subsequently sliced into 16µm sections with a cryostat and thaw
mounted

on

glass

slides.

The

brains

were

harvested,

post

fixed

in

4%

paraformaldehyde, and immersed in 20% followed by 30% sucrose in phosphate
buffered saline (PBS). Brains were frozen and sliced into 30 μm sections with a cryostat.
Coronal sections were taken at six points from 1.7 to -3.3 mm from Bregma. Sections
were either thaw mounted on glass slides or placed in Walter’s Anti-freeze
cryopreservative and stored at -20°C. All tissue processing was done under limited
lighting to protect the CFSE dye.
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Fluoro-Jade Staining
Brain sections mounted on glass slides were stained with Fluoro-Jade, which labels
degenerating neurons.

This method was adapted from that originally developed by

Schmued et al. (Schmued et al. 1997) and has been described by Duckworth et al.
(Duckworth et al. 2005). Slides were dried, placed in 100% ethanol for 3 min, 70%
ethanol for 1 min, and then ddH2O for 1 min. Slides were oxidized using a 0.06% KMnO4
solution for 15 min followed by three 1 min rinses with ddH2O. Slides were stained in a
0.001% solution of Fluoro-Jade (Histochem, Jefferson, AR) in 0.1% acetic acid in the
dark for 30 min. Slides were rinsed 4 times with ddH2O for 3 min each time, allowed to
dry at 45°C for 20 min, cleared with xylene and then cover slipped with DPX mounting
medium (Electron Microscopy Sciences, Ft. Washington, PA).

Infarct Quantification
Fluoro-Jade stained tissue was digitally photographed with Zeiss Axioskop2 (Carl Zeiss
Inc, Thornwood, NY) microscope controlled by Openlab software (Improvision, Waltham,
MA) at a magnification of 1x. Area of neurodegeneration was measured using the NIH
ImageJ software. To compensate for possible edema in the ipsilateral hemisphere, the
area of the contralateral hemisphere was also measured. Infarct volumes were then
calculated by the total area of ipsilateral staining divided by the total contralateral area
for a given animal. Infarct quantification was done for all animals.

Immunohistochemistry
The slides were dried at 45oC for 1 h then rinsed with PBS pH 7.4. Endogenous
peroxidase activity was extinguished by incubating the slides for 20 min in 3% hydrogen
peroxide. Slides were placed in permeabilization buffer containing 10% serum, 3% 1M
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lysine, and 0.3% Triton X-100 in PBS for 1 h at room temperature. Next, sections were
incubated overnight at 4°C in a primary antibody solution (PBS with 2% serum and 0.3%
Triton X-100) in a humidified chamber. Slides were subsequently washed with PBS and
incubated with a secondary antibody solution (PBS, 2% serum, 0.3% Triton X-100) for 1
h. For staining with metal-enhanced 3, 3’-diaminobenzidine (DAB) visualization sections
were washed in PBS (3 x 5 min) following secondary antibody solution and incubated in
an avidin/biotin/horseradish peroxidase complex (Vectastain Elite ABC kit; Vector
Laboratories, Burlingame, CA) for 1 h at room temperature. Sections were washed in
PBS, and DAB (Pierce, Rockford, IL) was used for color development. Slides were
washed thoroughly with PBS and dried for 1 h at 45°C then dehydrated, rinsed with
xylene and cover slipped using DPX.

For fluorescence staining, the same procedure was followed up to the incubation with
the fluorescently labeled secondary antibody, though sections were not incubated in
hydrogen peroxide. Slides were washed with PBS after secondary incubation, dried,
rinsed in xylene, and then cover slipped using DPX. Slides were protected from light
during these steps. Double-labeled immunohistochemistry, for CFSE and immune cell
surface markers or IFNγ was achieved by incubating the slides with primary
antibodies, followed by incubation with secondary antibodies conjugated to 594nm
fluorophores as CFSE fluoresces at 488nm.

The following primary antibodies were used: goat anti-rat IFNγ (1:200; R&D Systems,
Minneapolis, MN), mouse anti-rat CD3 for T cells (1:2,000; BD Biosciences, San Jose,
CA), mouse anti-rat CD161 for NK cells (1:1,000; Serotec, Raleigh, NC), and mouse
anti-rat CD11b for microglia/macrophages (1:3,000; Serotec). Anti-fluorescein antibodies
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were used to detect the presence of any CFSE molecules: Alexa-Fluor® 488 goat-anti
fluorescein (1:1,000; Invitrogen, Carlsbad, CA) and biotinylated rabbit anti-fluorescein
(1:3,000; Invitrogen). Alexa-Fluor® 594 rabbit anti-mouse (1:300; Invitrogen) secondary
was used in conjunction the immune cell surface markers. Alexa-Fluor® 594 goat antirabbit (1:300; Invitrogen) were used as secondary antibodies for IFNγ.

Image Capture
Tissue sections that were double labeled were viewed on the Leica SP2 confocal
microscope (Leica Microsystems, Buffalo Grove, IL). Images were taken at a
magnification of 63x. Each fluorophore was scanned sequentially and then the two
images were merged.

Splenic Cell Counts
Fresh spleens from the CFSE injected rats were removed prior to perfusion, weighed,
and placed in RPMI complete in stomacher bags. The spleens were disassociated and
strained with a 70µm filter into a 50 ml conical. The volume of the conical was brought
up to 40 ml. The cells were pelleted by centrifuging at 1500rpm for 5 min. The
supernatant was discarded and the cells were resuspended in 5 ml of ACK lysis buffer
(0.15M NH4Cl, 1M KHCO3, 0.1M Na2EDTA in water pH equaled 7.4) for 5 min. The
volume was adjusted to 40 ml with RPMI complete and then centrifuged at 1500rpm for
5 min. The supernatant was discarded and the cells were resuspended in 30 ml RPMI
complete. Cells were counted using Trypan Blue exclusion of dead cells. Additionally,
40µl of the solution was placed on a slide and cover slipped with a 22mm circular cover
slip (380mm2), three slides were used per spleen to obtain CFSE cell counts for each
spleen. Using a reticle with a 10x10 grid (1mm2 area with 10x objective using Zeiss
AxioSkop2 microscope, Carl Zeiss Inc) cells were counted in three different areas on
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each cover slip. A total number of CFSE positive cells and total number of cells for each
area was recorded and then the nine total counts for each rat were averaged to give
total number of CFSE positive cells and the percentage stained with CFSE for each time
point.

Giemsa Staining and Analysis
Giemsa staining was used to identify the immune cell types within circulation following
MCAO. Blood samples were obtained using cardiac puncture at the time of euthanasia.
Blood smears were made on by placing a small drop of blood on a non-charged slide. All
slides were air dried then fixed with methanol for 5 min. For Giemsa staining slides were
washed with distilled water three times for 2 min. The slides were then submerged in
Giemsa (Sigma-Aldrich, St. Louis, MO) stain for 4 min. The reaction was stopped by
adding distilled water. To remove excess staining an additional three washes with
distilled water were performed for 3 min each. Slides were then dried overnight and
cover slipped with DPX mounting media. These slides were then used to count the total
number of CFSE positive cells on the slide and identify these cells, as well as get a
leukocyte count for each animal.

The total number of CFSE cells was determined by counting the number of cells on the
total slide, two slides per animal. The cells were also indentified using the Giemsa
staining. Additionally leukocytes were counted by indentifying 100 cells per slide, two
slides per animal.

Statistical Analysis
All data are expressed as group mean ± SEM. Significance of the data was determined
by ANOVA with a Dunnet’s post hoc test for the spleen weights and the CFSE cells in
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the blood. A Tukey’s post hoc test was used for the CFSE cells in the spleen. A value of
p<0.05 was considered significant. All sections were blinded prior being analyzed by an
investigator.

Results
The Spleen Transiently Decreases in Size following MCAO in Rats
Spleens were weighed at different time points following MCAO. Spleen weights were
measured at 3, 24, 48, 51, 72, and 96 h post-MCAO and sham procedure. Previously we
have demonstrated 96 h post-MCAO as the time point at which the infarct is stable in
this permanent model of MCAO (Newcomb et al. 2006). The spleen was found to
significantly decrease in size at 24, 48, and 51 h following MCAO compared to sham
operated animals (p<0.05). However, spleen weights were not significantly different from
sham controls at 3, 72 and 96 h post-MCAO (Fig 8).

CFSE is a Safe and Effective Method to Label and Track Splenocytes in vivo
To track splenocyte migration following MCAO, rat spleens were injected with CFSE to
label splenocytes in vivo. None of the animals injected appeared ill or died (data not
shown). To determine if the presence of CFSE adversely affected splenic cells, Trypan
blue exclusion was utilized to assess cell viability. There was no difference in the
number of live splenocytes at any of the time points tested (Fig 9A). Additionally CFSE
labeled approximately 20 percent of splenocytes by five days (Fig 9B). The CFSE
injections did not alter infarct volume (data not shown).
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Changes in the Number of CFSE Positive Cells within the Spleen following MCAO
The CFSE only group received splenic injections of CFSE and was euthanized five days
later, the time point at which the remaining groups received sham or MCAO surgery. The
total number of CFSE positive splenocytes was decreased in the 48 h MCAO group
compared to the 48 h sham and the CFSE only groups

(p<0.0001; Fig 10). No

differences were detected between the 96 h MCAO and sham groups.

MCAO Induces Changes in Circulating Leucocytes and CFSE Positive Cells
Circulating CFSE positive cells were identified by using blood smears and the cell types
were determined using Giemsa staining. When blood smears from all the different
groups were compared, an overall increase in CFSE positive cells was observed in
circulation 48 h following MCAO (p<0.0007). This increase resulted in an increase in
circulating lymphocytes (p<0.005), neutrophils (p<0.0005), and monocytes (p<0.02).
Giemsa staining revealed a significant increase in lymphocytes at 48 h post-MCAO and
in the 96 h sham and MCAO groups (p<0.001). Neutrophils were significantly increased
in the 48 h MCAO and 96 h sham groups (p<0.001). In contrast, monocytes were
significantly decreased in all groups compared to the CFSE only (p<0.0001) (Table 1).

CFSE Cells Migrate to the Brain post-MCAO
CFSE labeled cells were present in the brains in the ipsilateral hemisphere of animals
that underwent the MCAO procedure only and not in the sham operated animals (Fig
11A and D). The cells were mainly located in the striatum of the injured brain at 48 and
96 h post-MCAO (Fig 11B and E). Upon higher magnification cells remained within the
cerebral vascular, not extravasating into the brain parenchyma (Fig 11C and F).
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Identification of CFSE Positive Cells in the Brain following MCAO
To identify the types of CFSE labeled cells in the brain following MCAO, double labeling
with staining for immune cell surface markers was employed. The double labeling
demonstrated the presence of CFSE positive monocytes (CD11b) and NK cells (CD161)
at 48 h post-MCAO (Fig 12A and B). At 96 h following MCAO monocytes, NK cells and T
cells (CD3) were present (Fig 12C-E). There were not any CFSE positive T cells in the
brains of animals 48 h post-MCAO (data not shown).

IFNγ Production by CFSE Labeled Cells in the Brain
Since IFNγ is a potent inflammatory cytokine, IFNγ production by CFSE cells was
assessed. Double labeling for IFNγ was performed on brain sections to determine if any
of the CFSE positive cells were expressing this cytokine. IFNγ staining co-localized with
CFSE at 96 h post-MCAO (Fig 13) but not at 48 h following MCAO (data not shown).

Discussion
The spleen is a highly proinflammatory organ following ischemic brain injuries (Ajmo et
al. 2008; Lee et al. 2008; Li et al. 2011; Das et al. 2011) as well as ischemic liver
(Okuaki et al. 1996), intestine (Savas et al. 2003), kidney (Jiang et al. 2007), and heart
(Leuschner et al. 2010) injury. In animal studies splenectomy reduces injury in all of
these organs. The spleen uses both a cellular and humoral response to tissue injuries.
The humoral response has been characterized following stroke since there are many
reports citing the splenic production of inflammatory cytokines and chemokines after this
type of brain injury. These cytokines include increased IFNγ protein following MCAO in
rats (Seifert et al. 2012). Increased cytokine mRNA for interleukin 1 beta (IL-1β)
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(Schwarting et al. 2008; Lee et al. 2008), TNFα (Lee et al. 2008; Schwarting et al. 2008;
Hurn et al. 2007), IFNγ (Hurn et al. 2007), and IL-6 (Hurn et al. 2007; Lee et al. 2008)
have been found in mice or rats following ischemic or hemorrhagic stroke. Chemokine
mRNA for CXCL2 and CXCL10 have been found to be elevated following MCAO in mice
(Offner et al. 2006a; Hurn et al. 2007). The cellular response has not been characterized
as well as the humoral response following stroke. There are some data in a mouse
model of transient MCAO (Offner et al. 2006b). However, cellular tracking has not been
utilized following stroke.

Other investigators have found that the spleen decreases in size following transient
MCAO in mice and that this decrease in spleen size is due to apoptosis of the cells and
a loss of functional centers within the spleen (Offner et al. 2006b). In rats, permanent
MCAO results in a transient decrease in spleen size from 24-72 h post-MCAO. This
effect is the result of a catecholamine surge following MCAO (Meyer et al. 2004) which
activates α1-adrenergic receptors on the splenic capsule causing a contraction of the
smooth muscles in the capsule. This leads to the transient decrease in splenic size
observed in rats. Blocking the α1-adrenergic receptors with prazosin or carvedilol
prevents the decrease in spleen size seen at 48 h following MCAO (Ajmo et al. 2009)
while carvedilol is also neuroprotective (Savitz et al. 2000; Ajmo et al. 2009). Contraction
of the splenic smooth muscle is associated with an increase in circulating white blood
cells and erythrocytes (Bakovic et al. 2005). The splenocytes which are released into
circulation following MCAO could account for the peripheral immune cells found in the
brain after stroke. While there are differences between Offner et al. (2006) and the
current findings this could be due the different species used in the studies, mice versus
rats, or the type of stroke surgery performed in each, transient MCAO versus permanent
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MCAO. Further investigations into how the spleen reacts to ischemic strokes in patients
will help elucidate the role the spleen plays in stroke pathogenesis.

The spleen responds to MCAO induced injury differently than injury associated with a
sham surgery. Sham operated rats at 48 h post-surgery have CFSE positive cell
populations within the spleen not different than CFSE only rats. MCAO rats in both the
48 h and 96 h groups and those in the 96 h sham group all have significantly decreased
CFSE positive cell populations within the spleen compared to CFSE only and 48 h sham
groups. This indicates that the brain injury induces a different splenic response, as
CFSE labeled cells are decreased in the spleen at 48 h post-MCAO compared to the 48
h sham operated group. The significant increase in circulating cells seen at 48 h postMCAO demonstrates the injury to the brain induces splenocyte migration. Another study
also found a decrease in splenocyte counts at 48 h post-MCAO compared to sham
operated rats (Gendron et al. 2002). However, the sham operation induces a delayed
splenic response as there is not a significant difference in the number of CFSE positive
cells within the spleen at 96 h in the sham or MCAO treated groups. This indicates that
the spleen does have a delayed response to a general insult like a sham operation. The
splenic response to the sham operation at 96 h is also supported by the similar
increases in circulating lymphocytes in both the 96 h MCAO and the 96 h sham groups.

Interestingly, while the spleen is decreased in size 48 h following MCAO, there is a
significant increase in the number of circulating CFSE positive cells, regardless of
immune cell type. The total number of circulating monocytes is decreased in all
treatment groups compared to the CFSE only group, which was used as a CFSE
injection control group. While the total number of circulating monocytes is decreased at
48 h there was a significant increase in CFSE positive monocytes demonstrating most of
83

the monocytes in circulation following MCAO at 48 h are from the spleen. This is also
consistent with evidence that there is a population of undifferentiated monocytes in the
spleen that are released into circulation and travel to the heart following myocardial
infarction in mice (Swirski et al. 2009). In a transient mouse MCAO model an increase in
circulating monocytes was observed at 96 h following MCAO (Offner et al. 2006b), which
is inconsistent with the data presented in this study. The differences again could be due
to the different models of MCAO and species used for each study. Additionally, few
CFSE positive cells were found in the thymus (data not shown).

Circulating CFSE positive cells were found only in the brains of MCAO treated rats at 48
and 96 h following MCAO. There were no CFSE positive cells in the brains of shamoperated rats at any time point. These CFSE positive cells were identified as NK cells
and monocytes at 48 h following MCAO, while at 96 h post-MCAO T cells were also
present. The cells appear to be localized to the blood vessels. While there is clear
documentation of the presence of immune cells within the infarct following MCAO
(Stevens et al. 2002), it does not appear that the majority of these cells are of splenic
origin. The types of immune cells found in the brain are consistent with the time course
for different immune cell populations to appear within the brain following stroke (Stevens
et al. 2002). Following the temporal pattern of immune cell infiltration 48 h post-MCAO,
there was the presence of monocytes and a lack of CFSE positive T cells. Additionally,
the presence of both T cells and monocytes 96 h post-MCAO is consistent with the
infiltration of these cells, as T cells are found later as part of the delayed adaptive
immune response (Stevens et al. 2002). The presence of these cells is known to
exacerbate delayed neural injury following stroke and removal of the spleen decreases
the number of peripheral immune cells that enter the brain (Ajmo et al. 2008; Seifert et
al. 2012). Therefore, if splenocytes are not entering the brain parenchyma, but
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enhancing the pro-inflammatory response to the injured neural tissue, then the cells
might be secreting inflammatory mediators. These inflammatory cytokines or
chemokines could be the method by which splenocytes are detrimental following stroke
versus being directly cytotoxic to neural cells. Secretion of proinflammatory cytokines
which activate microglia/macrophages at the site of injury would be detrimental to the
survival of neural cells following stroke.

One highly proinflammatory cytokine that activates microglia/macrophages, IFNγ, is
elevated in brains of rats post-MCAO (Seifert et al. 2012). Additionally, there is an
increase in IFNγ mRNA days following stroke in mice (Li et al. 2001), and blocking IFNγ
using neutralizing antibodies injected directly into the brain at 72 h post-MCAO is
neuroprotective (Liesz et al. 2009). At 96 h post-MCAO, CFSE positive cells were
producing IFNγ, which is consistent with the cell types that have been documented in the
brain 96 h following MCAO (Stevens et al. 2002). This production of IFNγ could
subsequently activate microglia/macrophages in a proinflammatory manner contributing
to increased neural injury. These data are consistent with the time when
microglia/macrophages become maximally activated following MCAO (Leonardo et al.
2010). While IFNγ producing cells were not found at 48 h following MCAO, there are
several other cytokines that could be produced by the cell types present early following a
stroke. Possible early proinflammatory mediators include IL-12, IL-8, IL-18, and CXCL2.
IL-12 and IL-18 are strong inducers of IFNγ synthesis by T cells and NK cells (Schroder
et al. 2004). While IL-8 and CXCL2 are highly chemotaxic and both are up regulated
following MCAO (Newman et al. 2005; Hurn et al. 2007; Offner et al. 2006a). Expression
of any or all of these molecules would increase neural injury following stroke.
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This set of experiments has identified the cellular splenic response following permanent
MCAO in rats using CFSE as a way to track immune cell migration following MCAO.
There is a transient decrease in splenic size, likely mediated by catecholaminergic
activity following stroke. This decrease in spleen size is associated with an increase in
circulating splenocytes which migrate to the brain and secrete the proinflammatory
cytokine

IFNγ.

This

production

of

IFNγ

coincides

with

the

time

when

microglia/macrophages are becoming maximally activated and have the ability to create
delayed neural injury. These data provide some insight into the mechanism by which the
spleen is detrimental in ischemic brain injuries and why splenectomy is neuroprotective
in these types of injuries. Further investigation into the splenic reaction in stroke patients
would provide insight into how the peripheral immune system can be modulated
following stroke to improve neurological outcomes.
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Figure 8: The spleen transiently decreases in size following MCAO in rats. Mean
spleen weights plotted over time following MCAO. Spleen weights were significantly
decreased by the 24, 48, and 51 h time points compared to sham operated controls (*
p<0.05). Spleen weights were not significantly different from sham operated controls at
the 3, 72, and 96 h time points.
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Figure 9: CFSE is a safe and effective method to label splenocytes in vivo. When
CFSE is injected directly into the spleen, it is not cytotoxic. CFSE was found to be safe
when used out to nine days following the initial injections (96 h post-MCAO) (A). Five
days following splenic injection of CFSE an average of 20% of splenocytes were CFSE
positive (B). The CFSE only group received splenic CFSE injections and was euthanized
5 days post injection, the same time point at which the other groups underwent MCAO or
sham surgery.
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Figure 10:

The number of CFSE positive cells within the spleen decreases

following MCAO. The total number of CFSE positive splenocytes was increased in the
48 h sham MCAO group compared to all the other groups except the CFSE only group (*
p<0.0001).
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Figure 11: CFSE cells migrate to the brain post-MCAO. Micrographs A, B and C are
from 48 h following surgery showing representative sections from sham (10X), MCAO
(10X) and MCAO (40X), respectively. Micrographs D, E and F are from 96 h following
surgery showing representative sections from sham (10X), MCAO (10X) and MCAO
(40X), respectively. CFSE labeled splenocytes are present in brain sections from the
rats that underwent MCAO and reside primarily in blood vessels. Scale bars for A, B, D,
and E = 100µm. Scale bars in C and F = 50µm.
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Figure 12: Identification of CFSE positive cells in the brain following MCAO. Brain
sections from CFSE treated rats at 48 and 96 h post-MCAO were immunostained with
antibodies that recognize CD161 (NK cell), CD11b (monocytes), and CD3 (T cell).
CD161 expression co-localized with CFSE labeled cells at 48 h (A) and 96 h (C). CD11b
co-localized with CFSE labeled cells at 48 h (B) and 96 h (D). CD3 immunoreactivity was
only detected with CFSE at 96 h (F). Arrows indicate double labeled cells. Scale bars =
50µm.
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Figure 13: IFNγ production by CFSE positive cells in the brain. Brain sections from
a CFSE injected rat at 96 h post-MCAO were immunostained with antibodies that
recognize IFNγ. Antibodies directed against IFNγ co-localized with CFSE labeled cells at
96 h. Arrow indicates area of co-localization of labeling. Scale bars = 50µm.
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Table 1: CFSE positive cells significantly increase in the blood at 48 h in MCAO
operated rats.

In 48 h post MCAO operated rats, CFSE positive cells were significantly increased in the
blood compared to all other groups (* p<0.0007). With Giemsa staining there was a
significant decrease in monocytes in the blood in all treatment groups compared to
CFSE only. There was an increase in lymphocytes in all surgery groups but was only
significant in the 48 h MCAO, 96 h sham and MCAO groups. Additionally there was an
increase in neutrophils in all groups that was only significant in the 48 h MCAO and 96 h
sham groups (* p ≤ 0.02).
a

CFSE only rats were euthanized at 5 days post injection, this is the same time point all

other groups underwent MCAO or sham surgery.
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Abstract
The delayed immune response to stroke is responsible for the increased neural injury
that continues to occur after the initial ischemic event. This delayed immune response
has been linked to the spleen, as splenectomy prior to middle cerebral artery occlusion
(MCAO) is neuroprotective. Previous studies have shown that the inflammatory cytokine
interferon gamma (IFNγ) is linked to the splenic response enhancing neural injury
following MCAO. Presence of IFNγ activates the expression of the inflammatory
interferon-inducible protein 10 (IP-10). This study was designed to determine if IP-10 via
IFNγ signaling is up regulated in the brain and spleen following MCAO. Expression of IP10 was found to increase in the brain and the spleen following MCAO. In an attempt to
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block IFNγ signaling and increases in IP-10 antibodies recognizing IFNγ where
administered. IFNγ neutralizing antibody administration reduced the levels of IP-10 in the
brain but not in the spleen. T cell infiltration was reduced in the MCAO-damaged brains
of the IFNγ antibody treated animals relative to ones receiving isotype antibodies.
Neutralizing IFNγ interferes with the pro-inflammatory cascade that involves IP-10 and
the recruitment of T cells to the brain following ischemic stroke.

Introduction
The spleen has been shown to be largely responsible for the peripheral immune
response which increases neural injury after ischemic stroke. The spleen is a large
reservoir for immune cells and splenectomy prior to middle cerebral artery occlusion
(MCAO) is neuroprotective in rats (Ajmo et al. 2008) and mice (Jin et al. 2013).
Interferon gamma (IFNγ) is a pro-inflammatory cytokine that relays the splenic response
to MCAO. IFNγ levels increase in the brain 72 h post MCAO in rats (Seifert et al. 2012b)
and mice (Jin et al. 2013). Splenectomy decreases the elevated levels of IFNγ in brain
following MCAO (Seifert et al. 2012b; Jin et al. 2013). Additionally, splenocytes have
been tracked in vivo following MCAO and these cells migrate to the injured brain (Seifert
et al. 2012a). Splenic IFNγ levels spike 24 h post MCAO (Seifert et al. 2012b) suggesting
the spleen plays a detrimental role following stroke through IFNγ.

It has been well documented that IFNγ increases following experimental stroke (Offner et
al. 2006; Hurn et al. 2007; Seifert et al. 2012b; Jin et al. 2013) and that blocking it is
neuroprotective (Liesz et al. 2009; Liesz et al. 2011; Yilmaz et al. 2006). Therefore,
interfering with IFNγ signaling should result in decreased infarct volume and reduced
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inflammation following stroke. This delayed increase in IFNγ protein in the brain following
MCAO indicates that this inflammatory cytokine is a relevant therapeutic target.
Downstream signaling of IFNγ

induces the expression of the chemokine interferon-

inducible protein 10 (IP-10), also known as CXCL10. IP-10 is a pro-inflammatory
chemokine that selectively drives the propagation of the Th1 response by interacting with
CXCR3 receptor (Loetscher et al. 2001). Microglia/macrophages produce IP-10 in
response to IFNγ stimulation (Luster 2002) and IP-10 cause the chemotaxis of Th1 cells
to the site of injury. In addition, IP-10 can prevent the activation of Th2 cells by
competitive antagonism of the CCR3 receptor (Loetscher et al. 2001). This interaction of
IP-10 with CXCR3 and CCR3 creates a pro-inflammatory feed forward mechanism
recruiting more IFNγ producing cells to the site of injury, leading to more IFNγ production
which in turn leads to more IP-10 production.

Studies on IP-10 in experimental stroke show that IP-10 mRNA is up regulated early in
the brain at 6 and 22 h following MCAO in mice. In the spleen IP-10 mRNA levels are
increased at 22 h post MCAO in mice (Offner et al. 2006; Hurn et al. 2007). Protein
levels of IP-10 have not been quantified in the brain or spleen following MCAO or at
longer time points after MCAO. Further investigation into the role of IP-10 following brain
ischemia will elucidate the IFNγ/T cell response in stroke.

This study was designed to determine if IP-10 protein levels are significantly elevated in
the brain and the spleen following MCAO. Previous studies have demonstrated
increased levels of IFNγ, the main inducer of IP-10 synthesis, in the brain (Seifert et al.
2012b; Jin et al. 2013) and the spleen post MCAO (Seifert et al. 2012b). A neutralizing
antibody directed against IFNγ was administered starting 24 h following MCAO to
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determine if delayed systemic blocking of IFNγ would result in reduced neural injury. IP10 levels were also measured in the spleen and the brain. T cell recruitment to the brain
was also investigated as IP-10 is a chemoattractant for Th1 cells. Blocking IFNγ will
provide insight into the entire IFNγ, IP-10, T cell recruitment inflammatory loop following
stroke.

Methods and Materials
Animal Care
All animal procedures were conducted in accordance with the NIH Guide for the Care
and Use of Laboratory Animals with a protocol approved by the Institutional Animal Care
and Use Committee at the University of South Florida. Male Sprague-Dawley rats (300350g) were used for the following experiments. All rats were purchased from Harlan
Labs (Indianapolis, IN), maintained on a 12 h light/dark cycle (6 am – 6 pm) and given
access to food and water ad libitum.

Laser Doppler Blood Flow Measurement
Laser Doppler was used to monitor blood perfusion (Moor Instruments Ltd, Devon,
England). A hole was drilled 1 mm posterior and 4 mm lateral from Bregma, and a guide
screw was placed. The laser doppler probe was inserted into the guide screw, and the
tip of the probe was placed against the surface of the brain. Rats that did not show ≥
60% reduction in perfusion during MCAO were excluded from this study (Ajmo et al.
2006; Ajmo et al. 2008; Hall et al. 2009). Sham operated rats had the guide screw and
laser doppler probe placed and blood flow was monitored to ensure that there was not a
drop in cerebral blood flow during the sham procedure.
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Permanent Middle Cerebral Artery Occlusion
MCAO surgery was performed using the intraluminal method originally described by
Longa et al. (Longa et al. 1989) and previously reported (Ajmo et al. 2006; Ajmo et al.
2008; Hall et al. 2009). Briefly, rats were anesthetized. Blunt dissection was
performed to isolate the common carotid artery, the internal carotid artery (ICA), and the
external carotid artery (ECA). The ECA was ligated and cut. Then a 40 mm
monofilament was introduced into the ECA, fed distally into the ICA, and advanced to the
origin of the MCA. The filament was tied off on the ECA to produce a permanent
occlusion. The incision was then sutured closed and the rat was allowed to wake in a
fresh cage.

Treatment Injections
A goat anti-rat polyclonal IFNγ neutralizing antibody (R&D Systems, Minneapolis, MN)
and a goat IgG isotype antibody (R&D Systems) were reconstituted with phosphate
buffered saline (PBS) to a concentration of 100 µg/ml. Animals in the antibody treatment
study were randomly assigned to one of three treatment groups: IFNγ neutralizing
antibody, IgG isotype control or the PBS control. Beginning at 24 h post MCAO animals
were administered either 5 µg (0.05 ml) of a goat anti-rat IFNγ neutralizing antibody, a
goat IgG isotype control, or an equivalent amount of PBS via an intraperitoneal (i.p.)
injection. Treatment was administered at 24, 48, and 72 h post MCAO.

Tissue Extraction and Sectioning
The animals were euthanatized with a ketamine/xylazine mix, 75 mg/kg and 7.5 mg/kg
respectively, i.p. at 24, 48, 72 or 96 h post-MCAO for the time course experiment and at
96 h post-MCAO for the antibody treatment experiment. Anesthetized animals were then
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perfused transcardially with 0.9% saline followed by 4% paraformaldehyde in phosphate
buffer (PB). The spleen and thymus were removed prior to perfusion. Spleens were
weighed immediately following removal and were subsequently snap frozen and stored
in the -80°C freezer with the thymi. The brains were harvested, post fixed in 4%
paraformaldehyde, and immersed in 20% followed by 30% sucrose in PBS. Brains were
frozen and sliced into 30 μm sections using a cryostat. Coronal sections were taken at
six points from 1.7 to -3.3 mm from Bregma. Sections were either thaw mounted on
glass slides or placed in Walter’s Anti-freeze cryopreservative and stored at -20°C.

Fluoro-Jade Staining
Brain sections mounted on glass slides were stained with Fluoro-Jade, which labels
degenerating neurons. This method was adapted from that originally developed by
Schmued et al. (Schmued et al. 1997) and has been described by Duckworth et al.
(Duckworth et al. 2005). Slides were dried at room temperature overnight, placed in
100% ethanol for 3 min, 70% ethanol for 1 min, and then ddH2O for 1 min. Slides were
oxidized using a 0.06% KMnO4 solution for 15 min followed by three 1 min rinses with
ddH2O. Slides were stained in a 0.001% solution of Fluoro-Jade (Histochem, Jefferson,
AR) in 0.1% acetic acid in the dark for 30 min. Slides then were rinsed 4 times with
ddH2O for 3 min each time, allowed to dry at 45°C for 20 min, cleared twice with xylene
and then cover slipped with DPX mounting medium (Electron Microscopy Sciences, Ft.
Washington, PA).

Infarct Quantification
Fluoro-Jade stained tissue was digitally photographed with Zeiss Axioskop2 (Carl Zeiss
Inc, Thornwood, NY) microscope controlled by Openlab software (Improvision, Waltham,
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MA) at a magnification of 1x. Area of neurodegeneration was measured using the NIH
ImageJ software. The area of the contralateral hemisphere was also measured and used
to compensate for possible edema in the ipsilateral hemisphere. Infarct volumes were
then calculated by the total area of ipsilateral staining divided by the total contralateral
area for a given animal. Infarct quantification was done for all animals.

Immunohistochemistry in the Brain
The slides were dried at 45°C for 1 h then rinsed with PBS pH 7.4. Endogenous
peroxidase activity was extinguished by incubating the slides for 20 min in 3% hydrogen
peroxide. Slides were placed in permeabilization buffer containing 10% serum, 3% 1M
lysine, and 0.3% Triton X-100 in PBS for 1 h at room temperature. Next, sections were
incubated overnight at 4°C in a primary antibody solution (PBS with 2% serum and 0.3%
Triton X-100) in a humidified chamber. Slides were subsequently rinsed with PBS and
incubated with a secondary antibody solution (PBS, 2% serum, 0.3% Triton X-100) for 1
h. For staining with metal-enhanced 3, 3’-diaminobenzidine (DAB) visualization sections
were rinsed with PBS following secondary antibody solution and incubated in an
avidin/biotin/horseradish peroxidase complex (Vectastain Elite ABC kit; Vector
Laboratories, Burlingame, CA) for 1 h at room temperature. Sections were washed in
PBS, and DAB (Pierce, Rockford, IL) was used for color development. Slides were
washed thoroughly with PBS and dried for 1 h at 45°C then dehydrated, rinsed twice
with xylene and cover slipped using DPX.

For fluorescence staining, the same procedure was followed up to the incubation with
the fluorescently labeled secondary antibody, though sections were not incubated in
hydrogen peroxide. Slides were rinsed with PBS after secondary incubation, dried,
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rinsed twice in xylene, and then cover slipped using DPX. Slides were protected from
light during these steps. Double-labeled immunohistochemistry, for IP-10 and immune
cell surface markers was achieved by incubating the slides with primary antibodies,
followed by incubation with secondary antibodies conjugated to 594nm or 488nm
fluorophores.

The following primary antibodies were used:

rabbit anti-rat IP-10 (1:5,000; abcam;

Cambridge, MA), mouse anti-rat CD3 for T cells (1:2,000; BD Biosciences, San Jose,
CA), and mouse anti-rat CD11b for microglia/macrophages (1:3,000; Serotec). AlexaFluor® 488 goat anti-rabbit (1:300; Invitrogen) secondary was used for all IP-10 staining.
Alexa-Fluor® 594 goat anti-mouse (1:300; Invitrogen) secondary was used in
conjunction the immune cell surface markers for double staining with IP-10. AlexaFluor® 488 rabbit anti-mouse (1:300; Invitrogen) secondary was used when only staining
for CD3 T cell.

IP-10 Immunohistochemistry in the Spleen
Spleens were fixed in 4% paraformaldehyde overnight. The spleens were then placed in
a solution of 20% glycerol and 2% dimethyl sulfoxide (DMSO) and embedded in a
gelatin matrix using MultiBrain Technology© (NeuroScience Associates, Knoxville, TN).
The block of spleens was rapidly frozen in isopentane with crushed dry ice (-70°C).
Using a microtome the block was sliced into 25 µm sections. Six consecutive sections
were taken and collected in Antigen Preservation solution (50% ethylene glycol, 49%
PBS pH 7.0, 1% polyvinyl pyrrolidone). The spleen sections were stained free floating in
Tris-buffered saline (TBS) solutions. Endogenous peroxide activity was extinguished by
treatment with 3% hydrogen peroxide for 15 min. After washing with TBS sections were
incubated for 30 min in permeabilization buffer (TBS with 0.3% TritonX-100 and 10%
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rabbit serum). Following permeabilization, slides were incubated overnight at room
temperature with primary antibody in TBS with 2% rabbit serum. The sections were
rinsed with TBS and incubated in secondary biotinylated antibody in TBS with 2% rabbit
serum for 1 h. After being rinsed with TBS, sections were incubated with an
avidin/biotin/horseradish peroxidase complex (Vectastain Elite ABC kit) for 1 h. Staining
was visualized with DAB (Sigma-Aldrich, St. Louis, MO). The sections were then
mounted on gelatinized slides, dried, dehydrated, cleared with xylene, and cover slipped
with Permount (Fischer Scientific, Pittsburg, PA). The primary antibody used was rabbit
anti-rat IP-10 (abcam) and the secondary antibody was biotinylated goat anti-rabbit
(Vector Laboratories,).

IP-10 Immunohistochemistry Quantification
IP-10 stained tissue sections were digitally photographed with Zeiss Axioskop2
microscope controlled by Openlab software at a 10x magnification. Three images from
each of 4 Bregma points (1.7 mm to -1.3 mm) were taken for a total of twelve images per
brain. The area selected for quantification was the striatum of the ipsilateral hemisphere
for all animals. The images were analyzed for percent of immunostaining per area with
ImageJ software. These twelve values were then averaged for each brain.

Splenic images were taken with a Nikon 90i microscope using a 20x objective and NIS
Elements BR 2.30 software at a high resolution. The images were processed and
analyzed with Photoshop CS5 (Adobe Systems Inc., San Jose, CA). The intensity of the
staining was measured in the histogram for the entire image and the amount of staining
per image was analyzed. Six sections per spleen were analyzed for each rat.
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Confocal Image Capture
Tissue sections that were double labeled were viewed on the Leica SP2 confocal
microscope (Leica Microsystems, Buffalo Grove, IL). Images were taken at a
magnification of 63x. Each fluorophore was scanned sequentially and then the two
images were merged.

Statistical Analysis
All data are expressed as group mean ± SEM. Significance of the data was determined
by ANOVA with Fischer’s Least Significant Difference post hoc test for all analysis. A
value of p<0.05 was considered significant. All sections were blinded prior being
analyzed by an investigator.

Results
IP-10 Levels are Elevated in the Brain following MCAO
To determine if IP-10 protein is expressed in the brain following MCAO, its protein
expression in the striatum of the ipsilateral hemisphere was characterized over time. To
quantify IP-10 levels, immunohistochemistry for IP-10 was performed on brain sections
from animals euthanized at 48, 72, and 96 h following MCAO and naïve or sham
operated rats. IP-10 protein levels were significantly increased at 72 h and remained
elevated at 96 h (p<0.01) compared to sham operated rats 96 h after surgery (Fig 14A).
Micrographs of representative sections from the striatum are depicted for naïve (Fig
14B), 48 h (Fig 14C), 72 h (Fig 14D), and 96 h post MCAO (Fig 14E).
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Splenic IP-10 Levels Increase after MCAO and Remain Elevated
In the spleen IP-10 protein levels were quantified using immunohistochemistry. Spleens
from animals euthanized 24, 48, 72, and 96 h post MCAO and sham or naïve rats were
used to perform immunohistochemistry to determine IP-10 protein expression. IP-10
levels were significantly elevated at 24 h and remained elevated out to 96 h following
MCAO compared to naïve spleens (p<0.0007). The sham operated animals had
increased levels of IP-10 but this did not reach statistical significance (Fig 15A).
Micrographs of representative sections from the spleen are depicted for naïve (Fig 15B),
sham (Fig 15C), 24 h (Fig 15D), 48 h (Fig 15E), 72 h (Fig 15F), and 96 h post MCAO
(Fig 15G).

IP-10 Producing Cells in the Brain following MCAO
IP-10 expression is induced by IFNγ in cells of the monocytic origin. Double staining with
IP-10 and CD11b, a marker for monocytes, was performed on the brains from animals
96 h post MCAO. IP-10 and CD11b co-localized in the striatum of the ipsilateral
hemisphere (Fig 16). This co-localization was determined using confocal microscopy.

IFNγ Neutralizing Antibody Administration Decreases Infarct following MCAO
To determine if the pro-inflammatory IFNγ signaling pathway contributes to increased
neural injury following MCAO, an IFNγ neutralizing antibody was administered 24, 48,
and 72 h post MCAO. Infarct volumes, as measured by Fluoro-Jade staining, were
significantly decreased in the IFNγ neutralizing antibody group compared to the vehicle
control (p<0.007). When compared to the IgG control the IFNγ antibody group was
approaching significance (p=0.0588) (Fig 17).
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IFNγ Neutralizing Antibody Decreased IP-10 in the Brain
IP-10 protein expression was quantified in the striatum of the ipsilateral hemisphere of
the IFNγ antibody, vehicle, and IgG treated rats. The IP-10 immunoreactivity was
significantly decreased in the IFNγ antibody treatment group compared to the IgG
isotype and PBS controls (Fig 18D). Representative micrographs from the striatum
demonstrate IP-10 staining was elevated in the PBS (Fig 18A) and IgG isotype control
(Fig 18B) groups compared to IP-10 staining in the IFNγ neutralizing antibody treated
group (Fig 18C).

IP-10 Levels in the Spleen Increase with Antibody Administration
IP-10 levels were measured in the spleen of animals treated with PBS, IgG isotype, or
IFNγ neutralizing antibody. Splenic IP-10 immunoreactivity was increased in the both the
antibody treated groups compared to the PBS treated group (Fig 19D). Representative
micrographs show reduced IP-10 staining in the spleens of PBS treated animals
compared to rats receiving an antibody (Fig 19A). IP-10 staining was increased equally
in the groups of animals that received an IgG (Fig 19B) or IFNγ antibody (Fig 19C).

The Amount of CD3 Immunoreactivity Appears to Decrease in the Brains of IFNγ
Antibody Treated Animals
Brain sections from animals that underwent MCAO and then administered an IFNγ
neutralizing antibody, an IgG isotype antibody, or PBS were stained using an anti CD3
antibody to visualize the presence of T cells. At 96 h post MCAO the amount of CD3
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immunostaining in the striatum appeared to be decreased in the IFNγ antibody treated
group (Fig 20C) compared to the IgG (Fig 20B) and PBS (Fig 20A) control groups.

Discussion
The spleen reacts to bodily injuries by eliciting an inflammatory response that further
exacerbates the cellular damage. Splenectomy is protective in a variety of ischemic
injuries in other organs including the liver (Okuaki et al. 1996), kidney (Jiang et al. 2007),
intestines (Savas et al. 2003), and heart (Leuschner et al. 2010). Additionally, removal of
the spleen is neuroprotective in several types of brain injuries including ischemic stroke
(Ajmo et al. 2008; Jin et al. 2013), intracerebral hemorrhage (Lee et al. 2008), and
traumatic brain injury (Li et al. 2011; Das et al. 2011; Walker et al. 2010). Radiation of
the spleen following MCAO also reduces infarct volume (Zhang 2013). The removal of
splenocytes either physically with splenectomy or with radiation results in protection from
ischemic injuries. Splenocytes mediate the expression of inflammatory cytokines and are
universally detrimental to ischemic injuries in mouse and rat injury models.

In the spleen the levels of IFNγ spike at 24 h post MCAO (Seifert et al. 2012b). This very
transient increase in IFNγ leads to a prolonged increase in the expression of IP-10 that
begins at 24 h and remains elevated at least out to 96 h post MCAO. This demonstrates
the long lasting effects IFNγ can have even when it is present for only a brief period of
time. IP-10 levels are increased in the sham operated animals but the increase is not as
high as the animals that underwent MCAO, suggesting the splenic response to a brain
injury could cause the production of higher levels of IP-10. The elevated levels of IP-10
at 24 h are consistent with data that found significantly higher mRNA levels of IP-10 in
the spleen 22 h following stroke in mice (Offner et al. 2006; Hurn et al. 2007).
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IP-10 levels in the brain parallel the expression pattern of IFNγ where expression does
not become elevated until 72 h and remain elevated at 96 h post MCAO. These results
are consistent with a delayed response and up regulation of protein compared to mRNA
levels. Studies looking at mRNA levels of IP-10 in the brain following MCAO found
increased mRNA as early as 6 h post MCAO (Offner et al. 2006). As expected, IP-10
within the infarct is expressed in cells of the monocytic lineage (CD11b+), which probably
are microglia. IFNγ is known to activate monocytes to produce IP-10 (Boehm et al.
1997). Studies that inhibited or neutralized IFNγ activity resulted in decreased infarcts.
The problem with these studies is that none of the methods used to inhibit IFNγ are
viable treatment options. IFNγ-/- mice had decreased infarct volumes compared to wild
type mice (Yilmaz et al. 2006). Inhibiting IFNγ with a neutralizing antibody injected
directly into the brain three days following MCAO decreased infarct volume (Liesz et al.
2009). Additionally, using an antibody directed at CD49d (very late antigen 4, VLA4)
prevented immune cells from entering the brain following MCAO leading to decreased
infarct volume. This treatment precluded the cells producing IFNγ from entering the
injured brain. Animals in this study were pretreated with antibody or administration was
started 3 h post MCAO, not extending the therapeutic window (Liesz et al. 2011). A
relevant approach to target IFNγ signaling would be to systemically administer an agent
directed against IFNγ activity after MCAO.

Systemic administration of an IFNγ neutralizing antibody significantly decreases infarct
volume when compared to vehicle controls. These results are consistent with previous
observations where IFNγ was blocked (Yilmaz et al. 2006; Liesz et al. 2009; Liesz et al.
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2011). Additionally, striatal IP-10 levels in the brain are significantly decreased with IFNγ
neutralization. The amount of CD3 immunoreactivity appears to be reduced in the
striatum of theses rats as well. This is expected as IFNγ is known to induce IP-10
production (Boehm et al. 1997) and IP-10 is a strong chemoattractant for proinflammatory IFNγ producing T cells (Groom and Luster 2011). The infarct volumes for
the IFNγ neutralizing antibody and the IgG control were approaching significance
demonstrating that an increase in the sample size is likely required to attain a statistically
significant level. Moreover, a potentially more effective approach would be to use these
antibodies in conjunction with pharmaceuticals that block the IFNγ or its downstream
intracellular signal transduction.

Administration of a goat antibody that is perceived by the immune system as foreign
resulted in a localized inflammatory response in the spleen. Both groups of rats that
received a goat antibody had elevated levels of IP-10 compared to the PBS control
group. IP-10 production can be induced in the presence of high levels of IFNβ or IFNα.
However, IFNγ is a more potent inducer of IP-10 (Groom and Luster 2011). The reaction
in the spleen is further evidence that a goat neutralizing antibody may not be the most
optimal method to inhibit IFNγ or its signaling. As mentioned above, agents exists that
block IFNγ receptor activation or its signaling. Its signaling is obstructed by Jak1/2 or
STAT1 inhibitors. There are several Jak1/2 inhibitors currently in clinical trials for
rheumatoid arthritis (RA) and cancer. One Jak1/2 inhibitor, INCB028050, is in clinical
trials for RA and in preclinical trials, using rats, 10mg/kg/d was found to decrease IFNγ
signaling by 65 percent in the animal model of RA (Fridman et al. 2010).
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IFNγ appears to be a strong target for stroke therapeutics. The reduction in IP-10 and T
cell recruitment are two positive effects of inhibiting IFNγ signaling. The next goal would
be to identify an agent that selectively targets IFNγ without causing an inflammatory
response itself. Targeting only the pro-inflammatory IFNγ response after stroke without
shutting down the whole immune system is a potential therapeutic approach worthy of
further investigation.
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Figure
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Immunohistochemical quantification of striatal IP-10 protein levels in the brains of naïve,
sham, 48, 72, and 96 h post MCAO demonstrate IP-10 levels are significantly elevated
at 72 and 96 h post MCAO compared to naïve brains (*p<0.01) (A). Representative
micrographs of IP-10 stained brains from naïve (B), 48 h (C), 72 h (D), and 96 h (E) post
MCAO. Scale bar = 100µm.
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Figure 15:

Quantification of IP-10 levels in the spleen post MCAO.

Immunohistochemical quantification of IP-10 protein levels in the spleens of naïve,
sham, 24, 48, 72, and 96 h post MCAO demonstrate IP-10 levels are significantly
elevated at 24 h and remain elevated out to 96 h post MCAO compared to naïve spleens
(*p<0.0007) (A). Representative micrographs of IP-10 stained spleens from naïve (B),
sham (C), 24 h (D), 48 h (E), 72 h (F), and 96 h (G) post MCAO. Scale bar = 120µm.
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Figure 16: IP-10 producing monocytes in the infarct following MCAO. Confocal
micrograph shows amoeboid CD11b positive cells (red) with intracellular IP-10 (green) in
the striatum of the ipsilateral hemisphere 96 h following MCAO. Scale bar equals 75µm.
Arrows indicate areas of co-localization.
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Figure 17: IFNγ neutralizing antibody administration following MCAO decreases
infarct volume. Administration of an IFNγ at 24, 48, and 72 h post MCAO significantly
decreased infarct volume at 96 h when compared to the vehicle group (*p<0.007). Infarct
volumes are decreased compared to isotype controls. However this did not reach
significance (# p=0.0588).
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Figure 18:

Quantification of IP-10 levels in the brain post MCAO with

administration of an IFNγ neutralizing antibody. Immunohistochemical quantification
of striatal IP-10 protein levels in the brains of vehicle, IgG isotype, and IFNγ antibody 96
h post MCAO demonstrate IP-10 levels are significantly decreased in the IFNγ antibody
treated group compared to the vehicle treated group (*p<0.009) (D). Representative
micrographs of IP-10 stained brains from vehicle (A), IgG isotype (B), and IFNγ antibody
(C) treatment groups 96 h post MCAO. Scale bars = 100µm.
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Figure 19:

Quantification of IP-10 levels in the spleen post MCAO with

administration of an IFNγ neutralizing antibody. Immunohistochemical quantification
of IP-10 protein levels in the spleens of vehicle, IgG isotype, and IFNγ antibody 96 h post
MCAO demonstrate IP-10 levels are elevated in the IFNγ antibody and the IgG groups
compared to the vehicle treated group (D). Representative micrographs of IP-10 stained
spleens from vehicle (A), IgG isotype (B), and IFNγ antibody (C) treatment groups 96 h
post MCAO. Scale bars = 120µm.
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Figure 20:

CD3 immunoreactivity appears to be decreased in IFNγ antibody

treated brains. The amount of T cells in the brain following MCAO appears to be
decreased. Images are from the striatum of the ipsilateral hemisphere. There appears to
be decreased CD3 (T cell) immunoreactivity in the brains of IFNγ antibody treated
animals (C) compared to the amount of staining in the two control groups vehicle (A) and
isotype (B). Scale bars equal 100µm. Arrows indicate areas of staining.
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Conclusion
Stroke is a complex neurologic disorder that occurs 795,000 times per year. It is the
leading cause of disability and the fourth leading cause of death. The current therapeutic
treatment for ischemic stroke is rTPA. Unfortunately only 3-5 percent of stroke patients
receive this treatment. Investigations into understanding the underlying mechanisms of
neural cell death have provided some insight into developing potential new therapies. A
majority of the initial work focused on the very early events that lead to neural injury,
including glutamate excitotoxicity (Ikonomidou and Turski 2002) and calcium
dysregulation (Cheng et al. 2004). Then the early immune response was recognized as
a contributing factor to neural injury and therapies were developed to target the immune
system with antibodies against intracellular adhesion molecule (ICAM) (Enlimomab
Acute Stroke Trial Investigators 2001). All of these therapies failed in clinical trials. There
have been many different speculations as to why these different agents failed. The
preliminary studies were done in rodent models of stroke but the rodent brain is different
from the human brain with regards to ratio of white to gray matter and the development
of the cortex. In other preliminary studies therapies were administered prior to
experimental stroke or at a clinically irrelevant time point. Additionally, most of the
preliminary studies were completed in healthy young male animals, which do not
accurately represent the human population that is most commonly affected by stroke.
Further research into the mechanisms of neural injury has lead to the discovery of the
role the immune system plays in enhancing delayed neural injury. Studies have
identified the immune cell types that are present in the brain at various time points
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following MCAO and have reported lymphocytes, T cells in particular, are increased in
the infarct days following stroke. Unlike monocytes and other innate immune cells, which
are present in the brain hours following stroke, T cells begin to significantly increase in
number around 72 h following MCAO (Stevens et al. 2002).

Other studies began to examine the adaptive immune response following MCAO and
found that lymphocytes play a detrimental role following stroke. SCID mice, which lack
the ability to produce lymphocytes, had decreased infarcts compared to WT mice at 96 h
following tMCAO (Hurn et al. 2007). Rag-/- mice, which are not capable of producing
lymphocytes, also had reduced infarcts compared to WT mice. When looking at specific
lymphocyte subtypes T cells both, CD4-/- (Th cells) and CD8-/- (cytotoxic T cells) mice,
had reduced infarcts compared to WT mice. However, B cell-/- mice did not have
significantly different infarct volumes when compared to WT mice, suggesting B cells do
not play a detrimental role following stroke (Yilmaz et al. 2006). These studies implicate
the peripheral immune system in the exacerbation of neural cell death following stroke.

The spleen is a reservoir of peripheral immune cells. Splenectomy prior to pMCAO
decreases infarct volume by 80% out to four days following pMCAO (Ajmo et al. 2008);
the infarct has stabilized by four days in our pMCAO model (Newcomb et al. 2006). In
addition to decreasing infarct size splenectomy also decreases the number of
neutrophils, (Ajmo et al. 2008) T cells, NK cells, and decreases microglia/macrophage
activation (Seifert et al. 2012). Removing the spleen decreases infarct volume after
tMCAO in mice (Jin et al. 2013) and reduces brain edema following ICH (Lee et al.
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2008). The mechanism behind the splenic response is poorly understood but the spleen
as a plausible therapeutic target for stroke.

Removing splenocytes has a beneficial effect on stroke outcomes. The exact role that
these cells play in exacerbating neural injury after stroke is unclear. These cells could be
migrating to the brain following stroke and increasing injury by cell mediated effects.
Splenocytes could also remain in the spleen and contribute to neural injury by releasing
inflammatory mediators like cytokines. It is also possible that both of these scenarios are
contributing to immune mediated cell death following stroke. While immune cells are
present in the brain after stroke, these could originate from other organs besides the
spleen. However, our data shows that splenocytes of monocytic and T cell origin migrate
to the injured brain but appear to remain in the blood vessels and release inflammatory
cytokines, such as IFNγ.

Cytokines have also been extensively studied in experimental models of stroke and in
stroke patients. These studies have lead to contradicting evidence regarding the role
certain

cytokines

play

following

stroke.

Some

cytokines

have

demonstrated

neuroprotective effects and other inflammatory cytokines are elevated too early to be a
therapeutic target. IL-1β is elevated in the brain within hours following stroke. IL-10 is
neuroprotective following experimental stroke and higher levels of plasma IL-10 are
associated with better outcomes in patients. TNFα has contradictory effects following
experimental stroke and its effects are dependent on its concentration. IL-6 has both
inflammatory and protective effects depending on the timing of its expression following
stroke. The majority of cytokines studied following experimental stroke are elevated early
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in the brain and produced by cells of the innate immune system. These contradictory
results at early time points after stroke have not lead to the development of any
therapeutics targeting any of the above mentioned cytokines, despite the fact that there
are FDA approved therapies which target TNFα and IL-6.

The adaptive immune system initiates a response days after stroke and targeting it
would extend the therapeutic window. IFNγ is a pro-inflammatory cytokine that is
primarily produced by the adaptive immune system. One of the primary mechanisms by
which IFNγ modulates the immune response is to activate cells of monocytic origin,
including microglia and macrophages. In response to a pathogen T cells and NK cells
produce IFNγ to activate and increase the cytotoxic properties of macrophages. The
primary goal of the Th1 response is to increase the killing of intracellular pathogens. IFNγ
is considered to be the signature cytokine associated with Th1 responses. This response
is the body’s major defense against viral and bacterial pathogens. However, elevated
levels of IFNγ following stroke as shown in our studies leads to increased cell death
through over activation of microglia/macrophage in the injured brain.

Previous work in our laboratory has shown microglia/macrophages become maximally
activated at 72 h post pMCAO (Leonardo et al. 2010). These data coincide with the
findings in aim 1 that IFNγ levels are elevated in the brain at 72 h after pMCAO. The
spleen is the mediator of the inflammatory response following stroke as demonstrating
that its removal reduces injury. Additional data from aim 1 indicate the spleen is a major
source of IFNγ, as levels spike at 24 h in the spleen and splenectomy prior to pMCAO
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reduces brain levels of IFNγ. Adding IFNγ systemically to splenectomized animals
reverses the protective effects of splenectomy and increases infarct volume to levels not
statistically different from sham splenectomized animals and brain IFNγ levels return to
levels seen in intact animals. Moreover, the effects of IFNγ are not directly toxic to
neural cells. Co-incubation with IFNγ during normoxia and OGD did not result in
significantly increased death to cultured neurons or oligodendrocytes. However,
neuronal cultures that contain IFNγ activated microglia did have significantly more cell
death (Bal-Price and Brown 2001). This suggests that IFNγ alone is not directly toxic to
neurons or OLs but if microglia are present then IFNγ activates these cells in a proinflammatory nature that is detrimental to neural cells.

Splenectomy provides further evidence that the splenic response is involved in
generating the inflammatory response in the brain following stroke. As splenectomy
reduces the amount of peripheral immune cells in the brain compared to sham
splenectomized animals. Cells from both the innate and adaptive immune systems are
significantly decreased in the brain with the absence of the spleen during stroke. NK and
T cells are the major source of IFNγ in the brain so the absence of these cells will result
in a reduced activation of microglia/macrophages. These data implicate the spleen in the
IFNγ inflammatory response and the peripheral immune cell response that increase
neural injury following MCAO.

These current studies on the role of IFNγ in stroke are supported by previously published
literature. IFNγ mRNA is increased in the brain beginning 48 h post MCAO and remained
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elevated out to six days (Li et al. 2001). Direct injection of an IFNγ neutralizing antibody
into the brain was only effective at reducing infarct if administered at 72 h following
tMCAO in mice and was not effective if administered 15 min post tMCAO (Liesz et al.
2009). Additionally, IFNγ-/- mice had reduced infarcts compared to WT mice following
tMCAO (Yilmaz et al. 2006). Microglia/macrophages become maximally activated at 72 h
following pMCAO (Leonardo et al. 2010) showing the presence of IFNγ is necessary for
the activation of these cells. IFNγ mRNA is increased in the spleen at 22 h following
tMCAO in mice (Hurn et al. 2007) supporting the finding that IFNγ levels spike within the
spleen at 24 h post pMCAO. Our findings with splenectomy and IFNγ have recently been
replicated in a mouse model of tMCAO (Jin et al. 2013) showing an identical response in
a different species and model of stroke. These experiments demonstrate there is a
connection between the spleen, IFNγ, and post stroke immune mediated neural injury.

The delay in increased IFNγ levels expressed in the injured brain suggests that the
splenocytes are migrating to the brain following ischemic stroke. Previous studies have
used knockout mice and irradiated WT mice injected with green fluorescent protein
(GFP) mouse bone marrow to study the reaction of the immune system to stroke. These
studies have shed important light on what types of cells are found in the brain following
stroke and identifying cells that are detrimental to neural cell survival after a stroke.
However, none of these studies have addressed the specific role splenocytes play in the
post stroke inflammatory reaction in the brain. The second aim labeled splenocytes with
CFSE prior to MCAO and tracked the migration of spleen cells following MCAO. This will
allow the use of an intact animal and still be able to track cells in vivo following MCAO
without using adoptive transfer of labeled cells.
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The spleen transiently decreases in size after pMCAO in rats from 24-72 h post pMCAO.
Increased circulating levels of CAs mediate this effect by activation of α1 adrenergic
receptors that are expressed on the splenic smooth muscle capsule. Administration of
prazosin, an α1 adrenergic blocker, prevents the decrease in spleen size observed at 48
h post pMCAO (Ajmo et al. 2008). Stress from a stroke induces increased circulating
levels of CAs in people and animals. Splenic contraction has been associated with
physically stressful situations, like repeated breath holds that result in repeated apneas.
The physical stress caused splenic contraction and the release of red and white blood
cells into circulation. This increase in circulating red and white blood cells does not occur
in splenectomized individuals (Bakovic et al. 2005). The changes in spleen size after
pMCAO determined the time points that were chosen for the study presented in aim 2,
when the spleen is decreased in size at 48 h and at 96 h post pMCAO when the spleen
has returned to size. CFSE was found to be nontoxic out to nine days post injection and
labels 20 percent of splenocytes at five days post injection. At 48 h there is a significant
decrease in splenic CFSE labeled cells and a concurrent significant increase in CFSE
positive cells in circulation following pMCAO which is not observed in sham MCAO or 96
h post MCAO. This increase in circulating splenocytes corresponds to the decrease in
spleen size, demonstrating that contraction of the spleen leads to the release of
splenocytes into circulation following pMCAO. This is consistent with data on splenic
contraction leading to increased circulating levels of red and white blood cells (Bakovic
et al. 2005).
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While there was an overall increase in circulating splenocytes there is an overall
decrease in circulating monocytes indicating the majority of these cells in circulation are
likely to be of splenic origin. This is consistent with findings that the spleen is a large
reservoir of undifferentiated non-tissue specific monocytes (Swirski et al. 2009). The
decrease in spleen size is consistent with the decrease in CFSE labeled splenocytes in
the spleen, and the increase in circulating CFSE labeled cells at 48 h in the pMCAO
group and not any of the other groups. The lymphocyte response also appears to be
pMCAO specific as they were significantly elevated in circulation in the 48 and 96 h
pMCAO groups and the 96 h sham MCAO. At 48 h following pMCAO the most likely
lymphocyte in the circulation are NK cells, as these cells are involved in the innate
immune response. T cells and B cells could be contributing to the increase seen at 48 h,
but these cells generally take longer to become activated. Further evidence of this
finding is that there are more lymphocytes in circulation at 96 h regardless of treatment.
This suggests the adaptive response is more robust at 96 h than at 48 h. With data
demonstrating splenocytes enter into circulation following pMCAO the injured brain was
examined for CFSE label splenocytes.

CFSE positive cells are found in the brains of rats at 48 and 96 h after pMCAO only and
not in the sham MCAO treated groups. Additionally, CFSE positive cells were only found
in the ipsilateral hemisphere. It has been previously published that immune cells are
present in the brain following MCAO (Stevens et al. 2002); however the tissue origin of
these cells was unknown. These data demonstrate that some of the immune cells found
in the brain after MCAO are directly from the spleen. Additionally double staining with
immune cell surface markers identified monocytes and NK cells at 48 h and monocytes,
NK cells, and T cells at 96 h post pMCAO. No CFSE positive T cells were found at 48 h
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following pMCAO. These data are consistent with previous data on the timing of the
migration of different immune cell populations into the brain following MCAO. Monocytes
have been found in the brain as early as 18 h post MCAO and are seen in the brain out
to 96 h following MCAO (Stevens et al. 2002). This is consistent with observing splenic
monocytes in the brain at 48 and 96 h post pMCAO. Additionally, T cells are not
observed in significant numbers in the brain until 72 h following MCAO (Stevens et al.
2002). This would explain why splenic T cells are present at 96 h and not at 48 h post
pMCAO.

Using confocal microscopy it appears as though the CFSE positive cells in the brain are
remaining in the vasculature and not extravasating into the infarct. Previous studies have
demonstrated the detrimental role splenocytes, or the spleen, have on neural injuries, as
splenectomy is neuroprotective prior to MCAO (Seifert et al. 2012; Jin et al. 2013; Ajmo
et al. 2008). If the splenocytes in the brain appear to be remaining in the vasculature this
makes it unlikely they are having directly cytotoxic effects on neural cells. Secretion of
cytokines is another method of how these cells could be negatively influencing cellular
survival within the infarct. Double staining indicated CFSE positive cells are producing
IFNγ in the brain at 96 h but not at 48 h following pMCAO. Other studies have
demonstrated that IFNγ protein levels are elevated at later time points in the brain
(Seifert et al. 2012; Jin et al. 2013), and that peripheral immune cells are the source of
IFNγ (Seifert et al. 2012). CFSE positive cells at 48 h could be producing any number or
combination of different cytokines or chemokines. For example, monocytes secrete
TNFα, IL-6, IL-12, IL-8, and the MCP family of chemokines (Boehm et al. 1997) all of
which could be detrimental to neural tissue within the infarct.
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IFNγ producing CFSE positive splenocytes were found in the ipsilateral hemisphere of
the brain 96 h following pMCAO. These data provide a connection between the spleen,
IFNγ, and the post stroke immune response. This connection suggests blocking IFNγ
signaling could be neuroprotective following pMCAO. One way to block IFNγ signaling
would be to neutralize circulating IFNγ with an antibody directed against it. In order to
demonstrate the efficacy of any treatment neutralizing IFNγ activity, expression of IFNγdependent IP-10 was analyzed. IP-10 is pro-inflammatory chemokine and a potent T cell
chemoattractant. The ability of IP-10 to modulate the Th1 response and the fact that IFNγ
induces a robust expression of IP-10 in activated cells makes this molecule an ideal
indicator of IFNγ activation. Aim 3 was designed to identify a molecular footprint of IFNγ
induced activation by investigating the expression profile of IP-10 following pMCAO and
determine the effects of neutralizing IFNγ with an antibody after pMCAO on IP-10
expression in the brain and spleen.

IP-10 expression in the brain is significantly increased at 72 h and remains elevated at
96 h post pMCAO. This expression profile mimics the expression of IFNγ in the brain
after pMCAO (Seifert et al. 2012). Splenic IP-10 expression is increased at 24 h and
remains elevated out to 96 h post pMCAO. However, unlike the brain, IP-10 expression
in the spleen does not mirror the response of IFNγ in the spleen that spikes at 24 h post
pMCAO and returns to sham operated levels (Seifert et al. 2012). The data from the
brain and the spleen are consistent with findings in mice following tMCAO where IP-10
mRNA is up regulated in the brain beginning at 6 h and remains elevated at 22 h. In the
spleen IP-10 mRNA is increased at 22 h post tMCAO (Hurn et al. 2007; Offner et al.
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2006). Microglia/macrophages are the main target cells of IFNγ and following pMCAO
monocytes (CD11b+ cells) are the primary source of IP-10 in the brain. This is consistent
with other reports that cells of monocytic origin produce IP-10 (Boehm et al. 1997).

To inhibit IFNγ signaling, a neutralizing antibody directed against IFNγ was administered
at 24, 48, and 72 h post pMCAO. The IFNγ neutralizing antibody significantly reduced
infarct volume at 96 h following pMCAO compared to the vehicle control group.
However, infarct volume was reduced but not significantly when the IFNγ antibody group
was compared to the IgG isotype control group (p=0.058). In addition to reducing infarct
volume, administration of an IFNγ neutralizing antibody significantly reduced the levels of
IP-10 protein in the brain at 96 h following pMCAO. However, administration of a goat
antibody, directed against IFNγ or the IgG isotype, resulted in increased levels of IP-10
in the spleen compared to vehicle treated rats 96 h post pMCAO. The decreased levels
of IP-10 in the brain demonstrate that IFNγ signaling is being inhibited by the neutralizing
antibody.

The spleen reacted in a pro-inflammatory manner to the presence of a

perceived threat of a foreign protein, the goat antibody. Both antibody treated groups
had increased splenic IP-10 levels compared to the vehicle group. While IFNγ is a potent
inducer of IP-10 it is not the only cytokine that can induce its production. TNFα, IFNα,
and IFNβ can all induce IP-10 production, especially when they are expressed in
combination (Groom and Luster 2011). Even activation of TLR4 can induce low levels of
IP-10 production (Luster 2002).

135

In addition to reducing IP-10 levels in the brain, the IFNγ neutralizing antibody also
appears to reduce the amount of T cells in the ipsilateral hemisphere 96 h following
pMCAO. IP-10 is a potent chemoattractant for Th1 cells and has the unique ability to act
as an antagonist on Th2 cells. IP-10 is a member of the CXC family of chemokines and
binds the CXCR3 receptor on Th1 cells which attracts more Th1 cells to the injured area,
in this case the brain. The recruitment of more Th1 cells increases the amount of IFNγ
and other pro-inflammatory mediators in the brain. IP-10 has the ability to simultaneously
inhibit the activation of Th2 cells by acting as an antagonist at the CCR3 receptor.
Studies have shown IP-10 binding to CCR3 prevents any of the CCR3 ligands from
binding the receptor and activating the cell (Loetscher et al. 2001). The ability of IP-10 to
recruit more pro-inflammatory Th1 cells and block the Th2 response creates a highly
inflammatory environment.

Blocking IFNγ activity after stroke appears to be an ideal approach to reducing neural
injury. The administration of a less immunogenic agent to interfere with IFNγ signaling
could prove to be a promising therapeutic. There are other points in the IFNγ signaling
pathway that could be targeted to blunt this response. IFNγ signals through Jak1/2, which
activate STAT1. Both points in the pathway could be targeted. There are currently
several Jak1/2 inhibitors in clinical trials for rheumatoid arthritis (RA) and cancer. One
inhibitor, INCB028050, is in clinical trials for RA and in preclinical studies using a rat
model of RA a dose of 10 mg/kg/d decreased IFNγ production by 65 percent (Fridman et
al. 2010).
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Selectively interfering with IFNγ and the Th1 response does not inhibit the other aspects
of the immune system. Different facets of the immune system are involved with tissue
repair and regeneration. Therefore, agents that suppress the immune system as a whole
are detrimental because they block the beneficial immune responses as well as the
responses that protect against infectious agents.

The Spleen, IFNγ, and IP-10: The Pro-Inflammatory Loop in Response to Stroke
Strokes involving occlusion of the MCA, which is the most commonly occluded vessel in
ischemic stroke patients, damage a number of frontal brain areas including the insular
cortex. The insular cortex is mainly perfused by the MCA. Insular cortical damage results
in sympathetic dysregulation and increased levels of circulating CAs in patients and
animals (Meyer et al. 2004; Cechetto et al. 1989). This increase in CAs has several
implications following stroke. Studies in rats suggest activation of α adrenergic receptors
on the splenic capsule causes splenic contraction and the release of splenocytes into
systemic circulation. Additionally CAs affect most immune cells, in particular Th cells.
Th1 cells express the β2 adrenergic receptor and when their activation increases the
intracellular levels of cyclic adenosine monophosphate (cAMP) activating protein kinase
A (PKA). This cascade inhibits Th1 cells from producing IL-2, IFNγ, and decreases
proliferation. However, Th2 cells do not express β2 receptors and are unaffected by CAs.
This would suggest that the immune system cannot generate a Th1 inflammatory
response following strokes that involve the MCA and could be happening in stroke
patients. However, naïve Th cells also express β2 receptors and when these receptors
are activated by the presence of CAs then naïve Th cells differentiate in response to an
antigen into Th1 cells. These cells have also been shown to produce two to four fold the
amount of IFNγ than cells not activated in the presence of CAs (Swanson et al. 2001).
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Moreover, the opening of the BBB by MMPs and other proteases along with the neural
cell death causes neural antigens to leak into systemic circulation (Herrmann et al. 2000;
Wunderlich et al. 1999). These antigens are seen as novel antigens to the immune
system as the BBB under normal conditions shields the brain from the immune system.
The spleen is a major site of blood filtration so it is possible then that after a stroke naïve
Th cells in the spleen are becoming activated against neural antigens in circulation.
With increased circulating levels of CAs, a pool of Th1 cells is created that are very
reactive to neural antigens. These cells could then lead to a pro-inflammatory IFNγ
driven immune response to the brain following stroke. This would result in two different
immune reactions occurring in the body at the same time, a blunted Th1 response to
pathogens and a strong Th1 response to the brain. Stroke patients that develop an
infection within 15 days of stroke onset have an increased Th1 response to neural
antigens and a poorer outcome at 90 days compared to patients that did not develop an
infection. This poor outcome occurred regardless of initial stroke severity (Becker et al.
2011).

This new pool of Th1 cells which are primed to respond to neural antigens with highly
elevated levels of IFNγ could explain the early spike in IFNγ in the spleen, which would
lead to the delayed increase in the brain. IFNγ levels in the brain become elevated at the
same time that microglia/macrophages are becoming maximally activated (Leonardo et
al. 2010). These cells in response to IFNγ produce ROS and increase recruitment of
more immune cells that results in more neural injury. Additionally microglia/macrophages
increase the expression of IP-10, which attracts more Th1 cells and blunts the Th2
response. Now a positive feedback loop has been set up where more Th1 cells produce

138

more IFNγ that activate more microglia/macrophages to produce more IP-10 to attract
more Th1 cells.

Removal of any piece of this loop: the spleen, T cells, or IFNγ, results in decreased
neural injury. The spleen appears to be the initial launch point for this response to
stroke. Splenectomy prior to MCAO reduces infarct volume, IFNγ levels in the brain, and
immune cell infiltration into the brain. Knockout mice have shown that knocking out all
lymphocytes, T cells, or IFNγ reduces infarct volume compared to WT mice. Selectively
blocking IFNγ also reduces infarct, IP-10 levels, and T cell recruitment. All of these
experiments selectively target an aspect of the inflammatory loop following stroke and
successfully decreases neural injury. This suggests the pro-inflammatory loop
established after a stroke is a potential therapeutic target. As previously mentioned
selectively targeting IFNγ only interferes with one facet of the immune response. This
leaves the other parts of the immune system that are critical to tissue repair,
regeneration and responding to infectious agents intact. An ideal stroke treatment will
extend the therapeutic window, decrease inflammation, and promote tissue repair.
Inhibiting IFNγ meets two of the three criteria by extending the treatment window from
4.5 h to 24 h and decreases inflammation. Blocking IFNγ signaling has the possibility to
indirectly promote tissue repair if the immune response is shifted from an inflammatory
tone to a more regenerative/repairing tone. Inhibiting IFNγ could also be combined with a
treatment that selectively targets tissue repair.
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Figure 21: Proposed treatments targeting the splenic response following stroke
to decrease neural injury. The splenic response to ischemic stroke can be detrimental.
Blocking IFNγ signaling following ischemic stroke leads to decreased neural injury by
decreasing interferon-inducible protein 10 (IP-10) and T cell recruitment to the injured
brain. This suggests inhibiting IFNγ signaling could be a stroke therapeutic.
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Payment terms and conditions, these terms and conditions shall control.
Jurisdiction
All disputes that may arise in connection with this present License, or the breach thereof,

shall be settled exclusively by arbitration, to be held in The Netherlands, in accordance
with Dutch law, and to be conducted under the Rules of the 'Netherlands Arbitrage
Instituut' (Netherlands Institute of Arbitration).OR:
All disputes that may arise in connection with this present License, or the breach
thereof, shall be settled exclusively by arbitration, to be held in the Federal Republic
of Germany, in accordance with German law.
Other terms and conditions:
v1.3
If you would like to pay for this license now, please remit this license along with
your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you
will be invoiced within 48 hours of the license date. Payment should be in the form
of a check or money order referencing your account number and this invoice number
RLNK500962041.
Once you receive your invoice for this order, you may pay your invoice by credit
card. Please follow instructions provided at that time.
Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
For suggestions or comments regarding this order, contact RightsLink Customer
Support:customercare@copyright.com or +1-877-622-5543 (toll free in the US) or
+1-978-646-2777.
Gratis licenses (referencing $0 in the Total field) are free. Please retain this
printable license for your reference. No payment is required.
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